

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 August 2006 (24.08.2006)

PCT

(10) International Publication Number
WO 2006/088921 A2

(51) International Patent Classification:

C07D 401/12 (2006.01) C07D 417/14 (2006.01)
C07D 401/14 (2006.01) A61K 31/445 (2006.01)
C07D 405/14 (2006.01) A61K 31/495 (2006.01)
C07D 413/14 (2006.01)

(21) International Application Number:

PCT/US2006/005267

(22) International Filing Date:

14 February 2006 (14.02.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/653,338 16 February 2005 (16.02.2005) US

(71) Applicants (for all designated States except US): **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US). **PHARMACOEPIA DRUG DISCOVERY, INC.** [US/US]; 3000 Eastpark Boulevard, Cranbury, New Jersey 08512 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROSENBLUM, Stuart, B.** [US/US]; 16 Steven Terrace, West Orange, New Jersey 07052 (US). **KIM, Seong, Heon** [KR/US]; 170 East McClellan Avenue, Livingston, New Jersey 07039 (US). **ZENG, Qingbei** [CN/US]; 509 Cinder Road, Edison, New Jersey 08820 (US). **WONG, Michael, K.C.** [CA/US]; 999 Hidden Lake Drive, Apt. 3D, North Brunswick, New Jersey 08902 (US). **ANILKUMAR, Gopinadhan, N.** [IN/US]; 560 Darwin Boulevard, Edison, New Jersey 08820 (US). **JIANG, Yueheng** [CN/US]; 5 Millstone Lane, Whitehouse Station, New Jersey 08889 (US). **YU,**

Wensheng [CN/US]; 46 Woodbury Road, Edison, New Jersey 08820 (US). **KOZLOWSKI, Joseph, A.** [US/US]; 1066 Stuart Road, Princeton, New Jersey 08540 (US). **SHIH, Neng-Yang** [US/US]; 4 Overlook Drive, Warren, New Jersey 07059 (US). **SHANKAR, Bandarpalle, B.** [US/US]; 1124 Van Arsdale Drive, Branchburg, New Jersey 08853 (US). **MCGUINNESS, Brian, F.** [US/US]; 16 Adams Court, Plainsboro, New Jersey 08536 (US). **DONG, Guizhen** [US/US]; 9 Aster Way, Dayton, New Jersey 08810 (US). **ZAWACKI, Lisa, Guise** [US/US]; 1226 Pebble Court, Yardley, Pennsylvania 19067 (US). **HOBBS, Douglas, W.** [US/US]; 1330 University Drive, Yardley, Pennsylvania 19067 (US). **BALDWIN, John, J.** [US/US]; 621 Gypsy Hill Circle, Gwynedd Valley, Pennsylvania 19437 (US). **SHAO, Yuefei** [CN/US]; 38 York Drive, Princeton, New Jersey 08540 (US).


(74) Agent: **BANERJEE, Krishna, G.**; Schering-plough Corporation, 2000 Galloping Hill Road, Patent Dept. K-6-1 1990, Kenilworth, New Jersey 07033-0530 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,

[Continued on next page]

(54) Title: PYRAZINYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY



(57) Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula (1): Chemical formula should be inserted here as it appears on the abstract in paper form. and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g., tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula (1).



RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished upon receipt of that report*

PYRAZINYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY

Field of the Invention

The present invention relates to novel pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity, pharmaceutical compositions containing one or more such antagonists, one or more such antagonists in combination with other compounds with chemokine activity, one or more such antagonists in combination with known immunosuppressive agents, non-limiting example(s) include Methotrexate, interferon, cyclosporin, FK-506 and FTY720, methods of preparing such antagonists and methods of using such antagonists to modulate CXCR3 activity. This invention also discloses methods of using such CXCR3 antagonists for the treatment (non-limiting examples include palliative, curative and prophylactic therapies) of diseases and conditions where CXCR3 has been implicated. Diseases and conditions where CXCR3 has been implicated include but are not limited to inflammatory conditions (psoriasis and inflammatory bowel disease), autoimmune disease (multiple sclerosis, rheumatoid arthritis), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, type I diabetes, viral meningitis and tuberculoid leprosy. CXCR3 antagonist activity has also been indicated as a therapy for tumor growth suppression as well as graft rejection (allograft and xenograft rejections for example).

BACKGROUND OF THE INVENTION

Chemokines constitute a family of small cytokines that are produced in inflammation and regulate leukocyte recruitment (Baggiolini, M. *et al.*, *Adv. Immunol.*, 55 : 97-179 (1994); Springer, T. A., *Annu. Rev. Physiol.*, 57 : 827-872 (1995); and Schall, T. J. and K. B. Bacon, *Curr. Opin. Immunol.*, 6: 865-873 (1994)). Chemokines are capable of selectively inducing chemotaxis of the formed elements of the blood (other than red blood cells), including leukocytes such as neutrophils, monocytes, macrophages, eosinophils, basophils, mast cells, and lymphocytes, such as T cells and B cells. In addition to stimulating chemotaxis, other changes can be selectively induced

by chemokines in responsive cells, including changes in cell shape, transient rises in the concentration of intracellular free calcium ions ($[Ca^{2+}]_i$), granule exocytosis, integrin upregulation, formation of bioactive lipids (e. g., leukotrienes) and respiratory burst, associated with leukocyte activation.

- 5 Thus, the chemokines are early triggers of the inflammatory response, causing inflammatory mediator release, chemotaxis and extravasation to sites of infection or inflammation.

The chemokines are related in primary structure and share four conserved cysteines, which form disulfide bonds. Based upon this conserved
10 cysteine motif, the family can be divided into distinct branches, including the C-X-C chemokines (α -chemokines) in which the first two conserved cysteines are separated by an intervening residue (e. g., IL-8, IP-10, Mig, I-TAC, PF4, ENA-78, GCP-2, GRO α , GRO β , GRO δ , NAP-2, NAP-4), and the C-C chemokines (β -chemokines), in which the first two conserved cysteines are
15 adjacent residues (e. g., MIP-1 α , MIP-1 β , RANTES, MCP-1, MCP-2, MCP-3, I-309) (Baggiolini, M. and Dahinden, C. A., *Immunology Today*, 15 : 127-133 (1994)). Most CXC-chemokines attract neutrophil leukocytes. For example, the CXC-chemokines interleukin 8 (IL-8), GRO alpha (GRO α), and neutrophil-activating peptide 2 (NAP-2) are potent chemoattractants and
20 activators of neutrophils. The CXC-chemokines designated Mig (monokine induced by gamma interferon) and IP-10 (interferon-gamma inducible 10 kDa protein) are particularly active in inducing chemotaxis of activated peripheral blood lymphocytes. CC-chemokines are generally less selective and can attract a variety of leukocyte cell types, including monocytes, eosinophils,
25 basophils, T lymphocytes and natural killer cells. CC-chemokines such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β) have been characterized as chemoattractants and activators of monocytes or
30 lymphocytes, but do not appear to be chemoattractants for neutrophils.

A chemokine receptor that binds the CXC-chemokines IP-10 and Mig has been cloned and characterized (Loetscher, M. *et al.*, *J. Exp. Med.*, 184 : 963-969 (1996)). CXCR3 is a G-protein coupled receptor with seven

transmembrane-spanning domains and has been shown to be restrictively expressed in activated T cells, preferentially human Th1 cells. On binding of the appropriate ligand, chemokine receptors transduce an intracellular signal through the associated G-protein resulting in a rapid increase in intracellular calcium concentration.

The receptor mediates Ca^{2+} (calcium ion) mobilization and chemotaxis in response to IP-10 and Mig. CXCR3 expressing cells show no significant response to the CXC-chemokines IL-8, $\text{GRO}\alpha$, NAP-2, GCP-2 (granulocyte chemotactic protein-2), ENA78 (epithelial-derived neutrophil-activating peptide 78), PF4 (platelet factor 4), or the CC-chemokines MCP-1, MCP-2, MCP-3, MCP-4, MIP-1 α , MIP-1 β , RANTES, I309, eotaxin or lymphotactin. Moreover, a third ligand for CXCR3, I-TAC (Interferon-inducible T cell Alpha Chemoattractant), has also been found to bind to the receptor with high affinity and mediate functional responses (Cole, K. E. *et al.*, *J. Exp. Med.*, 187: 2009-2021 (1998)).

The restricted expression of human CXCR3 in activated T lymphocytes and the ligand selectivity of CXCR3 are noteworthy. The human receptor is highly expressed in IL-2 activated T lymphocytes, but was not detected in resting T lymphocytes, monocytes or granulocytes (Qin, S. *et al.*, *J. Clin. Invest.*, 101: 746-754 (1998)). Additional studies of receptor distribution indicate that it is mostly CD3^+ cells that express CXCR3, including cells which are CD95^+ , CD45RO^+ , and $\text{CD45RA}^{\text{low}}$, a phenotype consistent with previous activation, although a proportion of CD20^+ (B) cells and CD56^+ (NK) cells also express this receptor. The selective expression in activated T lymphocytes is of interest, because other receptors for chemokines which have been reported to attract lymphocytes (e. g., MCP-1, MCP-2, MCP-3, MIP-1 α , MIP-1 β , RANTES) are also expressed by granulocytes, such as neutrophils, eosinophils, and basophils, as well as monocytes. These results suggest that the CXCR3 receptor is involved in the selective recruitment of effector T cells.

CXCR3 recognizes unusual CXC-chemokines, designated IP-10, Mig and I-TAC. Although these belong to the CXC-subfamily, in contrast to IL-8 and other CXC-chemokines which are potent chemoattractants for neutrophils, the primary targets of IP-10, Mig and I-TAC are lymphocytes,


particularly effector cells such as activated or stimulated T lymphocytes and natural killer (NK) cells (Taub, D. D. *et al.*, *J Exp. Med.*, 177: 18090-1814 (1993); Taub, D. D. *et al.*, *J. Immunol.*, 155: 3877-3888 (1995); Cole, K. E. *et al.*, *J. Exp. Med.*, 187: 2009-2021 (1998)). (NK cells are large granular lymphocytes, which lack a specific T cell receptor for antigen recognition, but possess cytolytic activity against cells such as tumor cells and virally infected cells.) Consistently, IP-10, Mig and I-TAC lack the ELR motif, an essential binding epitope in those CXC-chemokines that efficiently induce neutrophil chemotaxis (Clark-Lewis, I. *et al.*, *J. Biol. Chem.* 266: 23128-23134 (1991); Hebert, C. A. *et al.*, *J. Biol. Chem.*, 266 : 18989-18994 (1991); and Clark-Lewis, I. *et al.*, *Proc. Natl. Acad. Sci. USA*, 90 : 3574-3577 (1993)). In addition, both recombinant human Mig and recombinant human IP-10 have been reported to induce calcium flux in tumor infiltrating lymphocytes (TIL) (Liao, F. *et al.*, *J Exp. Med*, 182: 1301-1314 (1995)). While IP-10 has been reported to induce chemotaxis of monocytes *in vitro* (Taub, D. D. *et al.*, *J. Exp. Med.*, 177: 1809-1814 (1993), the receptor responsible has not been identified), human Mig and I-TAC appear highly selective, and do not show such an effect (Liao, F. *et al.*, *J. Exp. Med.*, 182: 1301-1314 (1995); Cole, K. E. *et al.*, *J. Exp. Med.*, 187: 2009-2021 (1998)). IP-10 expression is induced in a variety of tissues in inflammatory conditions such as psoriasis, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses and tuberculoid leprosy as well as tumors and in animal model studies, for example, experimental glomerulonephritis, and experimental allergic encephalomyelitis. IP-10 has a potent *in vivo* antitumor effect that is T cell dependent, is reported to be an inhibitor of angiogenesis *in vivo* and can induce chemotaxis and degranulation of NK cells *in vitro*, suggesting a role as a mediator of NK cell recruitment and degranulation (in tumor cell destruction, for example) (Luster, A. D. and P. Leder, *J. Exp. Med.*, 178: 1057-1065 (1993); Luster, A. D. *et al.*, *J Exp. Med.* 182: 219-231 (1995); Angiolillo, A. L. *et al.*, *J. Exp. Med.*, 182: 155-162 (1995); Taub, D. D. *et al.*, *J. Immunol.*, 155: 3877-3888 (1995)). The expression patterns of IP-10, Mig and I-TAC are also distinct from that of other CXC chemokines in that expression of each is induced by interferon-gamma (IFN γ), while the expression of IL-8 is down-regulated by IFN γ (Luster, A. D. *et al.*, *Nature*, 315 : 672-676 (1985); Farber, J. M., *Proc.*

Natl. Acad. Sci. USA, 87 : 5238-5242 (1990); Farber, J. M., *Biochem. Biophys. Res. Commun.*, 192 (1): 223-230 (1993), Liao, F. *et al.*, *J. Exp. Med.*, 182: 1301-1314 (1995); Seitz, M. *et al.*, *J. Clin. Invest.*, 87 : 463-469 (1991); Galy, A. H. M. and H. Spits, *J. Immunol.*, 147: 3823-3830 (1991);
5 Cole, K. E. *et al.*, *J. Exp. Med.*, 187 : 2009-2021 (1998)).


Chemokines are recognized as the long-sought mediators for the recruitment of lymphocytes. Several CC-chemokines were found to elicit lymphocyte chemotaxis (Loetscher, P. *et al.*, *FASEB J.*, 8: 1055-1060 (1994)), however, they are also active on granulocytes and monocytes (Uguccioni, M.
10 *et al.*, *Eur. J. Immunol.*, 25 : 64-68 (1995); Baggiolini, M. and C. A. Dahinden, *Immunol. Today*, 15 : 127-133 (1994)). The situation is different for IP-10, Mig and I-TAC, which are selective in their action on lymphocytes, including activated T lymphocytes and NK cells, and which bind CXCR3, a receptor which does not recognize numerous other chemokines and which displays a
15 selective pattern of expression.

In view of these observations, it is reasonable to conclude that the formation of the characteristic infiltrates in inflammatory lesions, such as, for example, delayed-type hypersensitivity lesions, sites of viral infection and certain tumors is a process mediated via CXCR3 and regulated by CXCR3
20 expression. Lymphocytes, particularly T lymphocytes, bearing a CXCR3 receptor as a result of activation can be recruited into inflammatory lesions, sites of infection and/or tumors by IP-10, Mig and/or I-TAC, which can be induced locally by interferon-gamma. Thus, CXCR3 plays a role in the selective recruitment of lymphocytes, particularly effector cells such as
25 activated or stimulated T lymphocytes. Accordingly, activated and effector T cells have been implicated in a number of disease states such as graft-rejection, inflammation, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (such as Crohn's disease and ulcerative colitis) and psoriasis. Thus, CXCR3 represents a promising target for the
30 development of novel therapeutics.


Reference is made to PCT Publication No. WO 93/10091 (Applicant: Glaxo Group Limited, Published May 27, 1993) which discloses piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation having the formula:



An illustrative compound of that series is:



- 5 Reference is also made to PCT Publication No. WO 9/20606
(Applicant: J. Uriach & CIA. S.A., Published April 29, 1999) which discloses
piperazines as platelet aggregation inhibitors having the formula:




- Reference is also made to US Patent Application No. US
10 2002/0018776 A1 (Applicant: Hancock, et al. Published February 14, 2002)
which discloses methods of treating graft rejection.

- Reference is also made to PCT Publication No. WO 03/098185 A2
(Applicant: Renovar, Inc., Published November 27, 2003) which discloses
methods of diagnosing and predicting organ transplant rejection by detection
15 of chemokines, for example, CXCR3 and CCL chemokines in urine.


- Reference is also made to PCT Publication No. WO 03/082335 A1
(Applicant: Sumitomo Pharmaceuticals Co. Ltd., Published October 9, 2003)
which discloses methods of screening a CXCR3 ligand and methods of
diagnosing type 2 diabetes by detecting the expression dose of a CXCR3
20 ligand in a biological sample.

Reference is also made to PCT Publication No. WO 02/085861
(Applicant: Millennium Pharmaceuticals, Inc. Published October 31, 2002)
which discloses imidazolidine compounds and their use as CXCR3
antagonists having the formula:




5

An illustrative compound of that series is:




Reference is also made to PCT Publication No. WO 03/101970
(Applicant: SmithKline Beecham Corporation, Published December 11, 2003)
which discloses imidazolium compounds and their use as CXCR3 antagonists
having the formula:




An illustrative example of that series is:

10




Reference is also made to US Patent Application No. US 2003/0055054 A1 (Applicant: Medina et al, Published March 20, 2003) which discloses compounds having the formula:




5

An illustrative compound of that series is:




Reference is also made to US Patent No. 6,124,319 (Applicant: MacCoss *et al.*, issued September 6, 2000) which discloses compounds useful as chemokine receptor modulators having the formula:

10



Reference is also made to PCT Publication WO 03/070242 A1 (Applicant: CELLTECH R& D limited, Published August 28, 2003) which

discloses compounds useful as "chemokine receptor inhibitors for the treatment of inflammatory diseases" having the formula:




There is a need for compounds that are capable of modulating CXCR3 activity. For example, there is a need for new treatments and therapies for diseases and conditions associated with CXCR3 such as inflammatory conditions (psoriasis and inflammatory bowel disease), autoimmune disease (multiple sclerosis, rheumatoid arthritis) and graft rejection (allograft and xenograft rejections for example) as well as infectious diseases, cancers and tumors, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, type I diabetes, viral meningitis and tuberculoid leprosy.

There is a need for methods of treatment or prevention or amelioration of one or more symptoms of diseases and conditions associated with CXCR3. There is a need for methods for modulating CXCR3 activity using the compounds provided herein.

SUMMARY OF THE INVENTION

In its many embodiments, the invention provides novel compounds of the Formula 1:



Formula 1

or pharmaceutically acceptable salts, solvates or esters thereof wherein:

X is N, O, alkyl, cycloalkyl, heteroaryl, heterocyclyl or heterocyclenyl;

ring D is a phenyl ring unsubstituted or optionally substituted with independently selected R^{20} moieties as stated below;

R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkyl, alkoxy, alkenyl, carbonyl, cycloalkyl, alkyl-cycloalkyl-, cycloalkenyl, alkylaryl, arylalkyl, aryl, amino, alkylamino, amidinyl, carboxamido, cyano, hydroxyl, urea, $-N\equiv CH$, $=NCN$, $-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNHSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-C(=S)N(H)alkyl$, $-N(H)-S(O)_2-alkyl$, $-N(H)C(=O)N(H)-alkyl$, $-S(O)_2alkyl$, $-S(O)_2N(H)alkyl$, $-S(O)_2N(alkyl)_2$, $-S(O)_2aryl$, $-C(=S)N(H)cycloalkyl$, $-C(=O)N(H)NH_2$, $-C(=O)alkyl$, -heteroaryl, heterocyclyl, and heterocyclenyl; or alternatively when X is N, the N taken together with the R^1 and R^2 forms a heterocycl, heteroaryl or $-N=C(NH_2)_2$;

R^3 and R^6 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, aralkyl, $-CN$, CF_3 , haloalkyl, cycloalkyl, halogen, hydroxyalkyl, $-N=CH-(R^{31})$, $-C(=O)N(R^{30})_2$, $-N(R^{30})_2$, $-OR^{30}$, $-SO_2(R^{31})$, $-N(R^{30})C(=O)N(R^{30})_2$ and $-N(R^{30})C(=O)R^{31}$;

R^7 and R^8 are the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, heteroaryl, hydroxyl, $-CN$, alkoxy, alkylamino, $-N(H)S(O)_2alkyl$ and $-N(H)C(=O)N(H)alkyl$; or alternatively R^7 and R^8 taken together is $=O$, $=S$, $=NH$, $=N(alkyl)$, $=N(Oalkyl)$, $=N(OH)$ or cycloalkyl;

the R^{10} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclenyl, heterocyclyl, alkylaryl, arylalkyl, $-CO_2H$, hydroxyalkyl, $-C(=O)N(R^{30})_2$, $-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-OR^{30}$, halogen, $=O$, and $-C(=O)R^{31}$;

the R^{11} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclenyl, alkylaryl, arylalkyl, hydroxyalkyl, carboxamide, CO_2H , $-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-OR^{30}$, halogen, $=O$, and $-C(=O)R^{31}$;

R^{12} is selected from the group consisting of H, alkyl, -CN, -C(=O)N(R³⁰)₂, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNHR³¹, -(CH₂)_qN(R³¹)₂, and -S(O₂)R³¹;

the R²⁰ moieties can be the same or different, each being

5 independently selected from the group consisting of H, alkyl, alkenyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylthiocarboxy, alkylheteroaryl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkenyl, aralkoxy, aralkoxycarbonyl, aralkylthio, aryl, aroyl, aryloxy, cyano, cycloalkyl, cycloalkenyl, formyl, guanidinyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, heterocyclenyl, hydroxyalkyl, haloalkoxy, hydroxamate, nitro, trifluoromethyl, trifluoromethoxy, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNH₂, -(CH₂)_qNHR³¹, -(CH₂)_qN(R³¹)₂, -(CH₂)_qC(=O)NHR³¹, - (CH₂)_qSO₂R³¹, -(CH₂)_qNHSO₂R³¹, -(CH₂)_qSO₂NHR³¹, -alkynylC(R³¹)₂OR³¹, -C(=O)R³⁰, -C(=O)N(R³⁰)₂, -C(=NR³⁰)NHR³⁰, -C(=NOH)N(R³⁰)₂, - C(=NOR³¹)N(R³⁰)₂, -C(=O)OR³⁰, -N(R³⁰)₂, -N(R³⁰)C(=O)R³¹, -NHC(=O)N(R³⁰)₂, -N(R³⁰)C(=O)OR³¹, -N(R³⁰)C(=NCN)N(R³⁰)₂, -N(R³⁰)C(=O)N(R³⁰)SO₂(R³¹), -N(R³⁰)C(=O)N(R³⁰)₂, -N(R³⁰)SO₂(R³¹), -N(R³⁰)S(O)₂N(R³⁰)₂, -OR³⁰, -OC(=O)N(R³⁰)₂, -SR³⁰, -SO₂N(R³⁰)₂, -SO₂(R³¹), -OSO₂(R³¹), -O(CH₂)_qSO₂R³¹, and -OSi(R³⁰)₃; or alternatively two R²⁰ moieties
10 are linked together to form a five or six membered aryl, cycloalkyl, heterocyclyl, heterocyclenyl, or heteroaryl ring wherein said five or six membered aryl, cycloalkyl, heterocyclyl, heterocyclenyl, or heteroaryl ring is fused to ring D and the fused ring is optionally substituted with 0-4 R²¹ moieties;

25 the R²¹ moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkenyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylthiocarboxy, alkylheteroaryl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkenyl, aralkoxy, aralkoxycarbonyl, aralkylthio, aryl, aroyl, aryloxy, carboxamido, cyano, cycloalkyl, cycloalkenyl, formyl, guanidinyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, heterocyclenyl, hydroxyalkyl, hydroxamate, nitro, trifluoromethoxy, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNH₂, - (CH₂)_qNHR³¹, -(CH₂)_qN(R³¹)₂, -(CH₂)_qC(=O)NHR³¹, -(CH₂)_qSO₂R³¹, - (CH₂)_qNSO₂R³¹, -(CH₂)_qSO₂NHR³¹, -alkynylC(R³¹)₂OR³¹, -C(=O)R³⁰, -

30

$C(=O)N(R^{30})_2$, $-C(=NR^{30})NHR^{30}$, $-C(=NOH)N(R^{30})_2$, $-C(=NOR^{31})N(R^{30})_2$,
 $-C(=O)OR^{30}$, $-N(R^{30})_2$, $-N(R^{30})C(=O)R^{31}$, $-NHC(=O)N(R^{30})_2$,
 $-N(R^{30})C(=O)OR^{31}$, $-N(R^{30})C(=NCN)N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})SO_2(R^{31})$,
 $-N(R^{30})C(=O)N(R^{30})_2$, $-N(R^{30})SO_2(R^{31})$, $-N(R^{30})S(O)_2N(R^{30})_2$, $-OR^{30}$,
 5 $-OC(=O)N(R^{30})_2$, $-SR^{30}$, $-SO_2N(R^{30})_2$, $-SO_2(R^{31})$, $-OSO_2(R^{31})$, and $-OSi(R^{30})_3$;

Y is selected from the group consisting of $-(CR^{13}R^{13})_r-$, $-CHR^{13}C(=O)-$,
 $-(CHR^{13})_rO-$, $-(CHR^{13})_rN(R^{30})-$, $-C(=O)-$, $-C(=NR^{30})-$, $-C(=N-OR^{30})-$,
 $-CH(C(=O)NHR^{30})-$, CH-heteroaryl-, $-C(R^{13}R^{13})_rC(R^{13})=C(R^{13})-$,
 $-(CHR^{13})_rC(=O)-$ and $-(CHR^{13})_rN(H)C(=O)-$; or alternatively Y is cycloalkyl,
 10 heterocyclenyl, or heterocyclyl wherein the cycloalkyl, heterocyclenyl, or
 heterocyclyl is fused with the phenyl ring marked D;

the R^{13} moieties can be the same or different, each being independently
 selected from the group consisting of H, alkyl, alkylaryl, cycloalkyl, alkoxy, aryl,
 heteroaryl, heterocyclenyl, heterocyclyl, spiroalkyl, $-CN$, $-CO_2H$, $-C(=O)R^{30}$,
 15 $-C(=O)OR^{31}$, $-C(=O)N(R^{30})_2$, $-(CHR^{30})_qOH$, $-(CHR^{30})_qOR^{31}$, $-(CHR^{30})_qNH_2$, $-(CH$
 $R^{30})_qNHR^{31}$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNSO_2R^{31}$, $-$
 $(CH_2)_qSO_2NHR^{31}$, $-NH_2$, $-N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})_2$, $-N(R^{30})SO_2(R^{31})$, $-OH$,
 OR^{30} , $-SO_2N(R^{30})_2$, and $-SO_2(R^{31})$;

the R^{30} moieties can be the same or different, each being
 20 independently selected from the group consisting of H, alkyl, alkylaryl, aryl,
 aralkyl, cycloalkyl, $-CN$, $-(CH_2)_qOH$, $-(CH_2)_qOalkyl$, $-(CH_2)_qOalkylaryl$, $-$
 $(CH_2)_qOaryl$, $-(CH_2)_qOaralkyl$, $-(CH_2)_qOcycloalkyl$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHalkyl$,
 $-(CH_2)_qN(alkyl)_2$, $-(CH_2)_qNHalkylaryl$, $-(CH_2)_qNHaryl$, $-(CH_2)_qNHaralkyl$, $-$
 $(CH_2)_qNHcycloalkyl$, $-(CH_2)_qC(=O)NHalkyl$, $-(CH_2)_qC(=O)N(alkyl)_2$, $-$
 25 $(CH_2)_qC(=O)NHalkylaryl$, $-(CH_2)_qC(=O)NHaryl$, $-(CH_2)_qC(=O)NHaralkyl$, $-$
 $(CH_2)_qC(=O)NHcycloalkyl$, $-(CH_2)_qSO_2alkyl$, $-(CH_2)_qSO_2alkylaryl$, $-$
 $(CH_2)_qSO_2aryl$, $-(CH_2)_qSO_2aralkyl$, $-(CH_2)_qSO_2cycloalkyl$, $-(CH_2)_qNSO_2alkyl$, $-$
 $(CH_2)_qNSO_2alkylaryl$, $-(CH_2)_qNSO_2aryl$, $-(CH_2)_qNSO_2aralkyl$, $-$
 $(CH_2)_qNSO_2cycloalkyl$, $-(CH_2)_qSO_2NHalkyl$, $-(CH_2)_qSO_2NHalkylaryl$, $-$
 30 $(CH_2)_qSO_2NHaryl$, $-(CH_2)_qSO_2NHaralkyl$, $-(CH_2)_qSO_2NHcycloalkyl$,
 heterocyclenyl, heterocyclyl, and heteroaryl;

the R^{31} moieties can be the same or different, each being
 independently selected from the group consisting of alkyl, alkylaryl, aryl,
 aralkyl, cycloalkyl, $-(CH_2)_qOH$, $-(CH_2)_qOalkyl$, $-(CH_2)_qOalkylaryl$, $-(CH_2)_qOaryl$,

$-(CH_2)_qOaralkyl$, $-(CH_2)_qOcycloalkyl$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHalkyl$, -
 $(CH_2)_qN(alkyl)_2$, $-(CH_2)_qNHalkylaryl$, $-(CH_2)_qNHaryl$, $-(CH_2)_qNHaralkyl$, -
 $(CH_2)_qNHcycloalkyl$, $-(CH_2)_qC(=O)NHalkyl$, $-(CH_2)_qC(=O)N(alkyl)_2$, -
 $(CH_2)_qC(=O)NHalkylaryl$, $-(CH_2)_qC(=O)NHaryl$, $-(CH_2)_qC(=O)NHaralkyl$, -
5 $(CH_2)_qC(=O)NHcycloalkyl$, $-(CH_2)_qSO_2alkyl$, $-(CH_2)_qSO_2alkylaryl$, -
 $(CH_2)_qSO_2aryl$, $-(CH_2)_qSO_2aralkyl$, $-(CH_2)_qSO_2cycloalkyl$, $-(CH_2)_qNSO_2alkyl$, -
 $(CH_2)_qNSO_2alkylaryl$, $-(CH_2)_qNSO_2aryl$, $-(CH_2)_qNSO_2aralkyl$, -
 $(CH_2)_qNSO_2cycloalkyl$, $-(CH_2)_qSO_2NHalkyl$, $-(CH_2)_qSO_2NHalkylaryl$, -
 $(CH_2)_qSO_2NHaryl$, $-(CH_2)_qSO_2NHaralkyl$, $-(CH_2)_qSO_2NHcycloalkyl$,

10 heterocyclenyl, heterocyclyl, and heteroaryl;

m is 0 to 4;

n is 0 to 4;

p is 0 to 5;

each q can be the same or different, each being independently

15 selected from 1 to 5; and

r is 1 to 4;

with the proviso that there are no two adjacent double bonds in any ring, and that when a nitrogen is substituted by two alkyl groups, said two alkyl groups may be optionally joined to each other to form a ring.

20 The present invention also provides novel compounds of the Formula 1, or pharmaceutically acceptable salts, solvates, or esters thereof, wherein:

X is N, O, alkyl, cycloalkyl, heteroaryl, heterocyclyl or heterocyclenyl;

ring D is a phenyl ring unsubstituted or optionally substituted with independently selected R^{20} moieties as stated below;

25 R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkyl, alkoxy, alkenyl, carbonyl, cycloalkyl, cycloalkenyl, alkylaryl, arylalkyl, aryl, amino, alkylamino, amidinyl, carboxamido, cyano, hydroxyl, urea, $-N\equiv CH$, $=NCN$, $-(CH_2)_qOH$,
 $-(CH_2)_qOR^{31}$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$,
 30 $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNH SO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-C(=S)N(H)alkyl$,
 $-N(H)-S(O)_2alkyl$, $-N(H)C(=O)N(H)-alkyl$, $-S(O)_2alkyl$, $-S(O)_2N(H)alkyl$,
 $-S(O)_2N(alkyl)_2$, $-S(O)_2aryl$, $-C(=S)N(H)cycloalkyl$, $-C(=O)N(H)NH_2$,
 $-C(=O)alkyl$, -heteroaryl, heterocyclyl, and heterocyclenyl; or alternatively

when X is N, the N taken together with the R¹ and R² forms a heterocycyl, heteroaryl or -N=C(NH₂)₂;

R³ and R⁶ moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, aralkyl, -CN, CF₃, haloalkyl, cycloalkyl, halogen, hydroxyalkyl, -N=CH-(R³¹), -C(=O)N(R³⁰)₂, -N(R³⁰)₂, -OR³⁰, -SO₂(R³¹), -N(R³⁰)C(=O)N(R³⁰)₂ and -N(R³⁰)C(=O)R³¹;

R⁷ and R⁸ are the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, heteroaryl, hydroxyl, -CN, alkoxy, alkylamino, -N(H)S(O)₂alkyl and -N(H)C(=O)N(H)alkyl; or alternatively R⁷ and R⁸ taken together is =O, =S, =NH, =N(alkyl), =N(Oalkyl), =N(OH) or cycloalkyl;

the R¹⁰ moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclenyl, heterocyclyl, alkylaryl, arylalkyl, -CO₂H, hydroxyalkyl, -C(=O)N(R³⁰)₂, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNHR³¹, -(CH₂)_qN(R³¹)₂, -OR³⁰, halogen, =O, and -C(=O)R³¹;

the R¹¹ moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclenyl, alkylaryl, arylalkyl, hydroxyalkyl, carboxamide, CO₂H, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNHR³¹, -(CH₂)_qN(R³¹)₂, -OR³⁰, halogen, =O, and -C(=O)R³¹;

R¹² is selected from the group consisting of H, alkyl, -CN, -C(=O)N(R³⁰)₂, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNHR³¹, -(CH₂)_qN(R³¹)₂, and -S(O₂)R³¹;

the R²⁰ moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkenyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylthiocarboxy, alkylheteroaryl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkenyl, aralkoxy, aralkoxycarbonyl, aralkylthio, aryl, aroyl, aryloxy, cyano, cycloalkyl, cycloalkenyl, formyl, guanidiny, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, heterocyclenyl, hydroxyalkyl, hydroxamate, nitro, trifluoromethoxy, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNH₂, -(CH₂)_qNHR³¹,

$-(CH_2)_qN(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNHSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-alkynylC(R^{31})_2OR^{31}$, $-C(=O)R^{30}$, $-C(=O)N(R^{30})_2$, $-C(=NR^{30})NHR^{30}$, $-C(=NOH)N(R^{30})_2$, $-C(=NOR^{31})N(R^{30})_2$, $-C(=O)OR^{30}$, $-N(R^{30})_2$, $-N(R^{30})C(=O)R^{31}$, $-NHC(=O)N(R^{30})_2$, $-N(R^{30})C(=O)OR^{31}$,
 5 $-N(R^{30})C(=NCN)N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})SO_2(R^{31})$, $-N(R^{30})C(=O)N(R^{30})_2$, $-N(R^{30})SO_2(R^{31})$, $-N(R^{30})S(O)_2N(R^{30})_2$, $-OR^{30}$, $-OC(=O)N(R^{30})_2$, $-SR^{30}$, $-SO_2N(R^{30})_2$, $-SO_2(R^{31})$, $-OSO_2(R^{31})$, and $-OSi(R^{30})_3$; or alternatively two R^{20} moieties are linked together to form a five or six membered aryl, cycloalkyl, heterocyclyl, heterocyclenyl, or heteroaryl ring wherein said five or six
 10 membered aryl, cycloalkyl, heterocyclyl, heterocyclenyl, or heteroaryl ring is fused to ring D and the fused ring is optionally substituted with 0-4 R^{21} moieties;

the R^{21} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkenyl, alkylaryl,
 15 alkynyl, alkoxy, alkylamino, alkylthiocarboxy, alkylheteroaryl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkenyl, aralkoxy, aralkoxycarbonyl, aralkylthio, aryl, aroyl, aryloxy, carboxamido, cyano, cycloalkyl, cycloalkenyl, formyl, guanidinyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, heterocyclenyl, hydroxyalkyl,
 20 hydroxamate, nitro, trifluoromethoxy, $-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-alkynylC(R^{31})_2OR^{31}$, $-C(=O)R^{30}$, $-C(=O)N(R^{30})_2$, $-C(=NR^{30})NHR^{30}$, $-C(=NOH)N(R^{30})_2$, $-C(=NOR^{31})N(R^{30})_2$, $-C(=O)OR^{30}$, $-N(R^{30})_2$, $-N(R^{30})C(=O)R^{31}$, $-NHC(=O)N(R^{30})_2$,
 25 $-N(R^{30})C(=O)OR^{31}$, $-N(R^{30})C(=NCN)N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})SO_2(R^{31})$, $-N(R^{30})C(=O)N(R^{30})_2$, $-N(R^{30})SO_2(R^{31})$, $-N(R^{30})S(O)_2N(R^{30})_2$, $-OR^{30}$, $-OC(=O)N(R^{30})_2$, $-SR^{30}$, $-SO_2N(R^{30})_2$, $-SO_2(R^{31})$, $-OSO_2(R^{31})$, and $-OSi(R^{30})_3$;

Y is selected from the group consisting of $-(CR^{13}R^{13})_r-$, $-CHR^{13}C(=O)-$, $-(CHR^{13})_rO-$, $-(CHR^{13})_rN(R^{30})-$, $-C(=O)-$, $-C(=NR^{30})-$, $-C(=N-OR^{30})-$,
 30 $-CH(C(=O)NHR^{30})-$, CH-heteroaryl-, $-C(R^{13}R^{13})_rC(R^{13})=C(R^{13})-$, $-(CHR^{13})_rC(=O)-$ and $-(CHR^{13})_rN(H)C(=O)-$; or alternatively Y is cycloalkyl, heterocyclenyl, or heterocyclyl wherein the cycloalkyl, heterocyclenyl, or heterocyclyl is fused with the phenyl ring marked D;

the R^{13} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, cycloalkyl, alkoxy, aryl, heteroaryl, heterocyclenyl, heterocyclyl, spiroalkyl, -CN, -CO₂H, -C(=O)R³⁰, -C(=O)N(R³⁰)₂, -(CHR³⁰)_qOH, -(CHR³⁰)_qOR³¹, -(CHR³⁰)_qNH₂, -(CHR³⁰)_qNHR³¹, -
 5 (CH₂)_qC(=O)NHR³¹, -(CH₂)_qSO₂R³¹, -(CH₂)_qNSO₂R³¹, -(CH₂)_qSO₂NHR³¹, -NH₂, -N(R³⁰)₂, -N(R³⁰)C(=O)N(R³⁰)₂, -N(R³⁰)SO₂(R³¹), -OH, OR³⁰, -SO₂N(R³⁰)₂, and -SO₂(R³¹);

the R^{30} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, aryl,
 10 aralkyl, cycloalkyl, CN, -(CH₂)_qOH, -(CH₂)_qOalkyl, -(CH₂)_qOalkylaryl, -(CH₂)_qOaryl, -(CH₂)_qOaralkyl, -(CH₂)_qOcycloalkyl, -(CH₂)_qNH₂, -(CH₂)_qNHalkyl, -(CH₂)_qN(alkyl)₂, -(CH₂)_qNHalkylaryl, -(CH₂)_qNHaryl, -(CH₂)_qNHaralkyl, -(CH₂)_qNHcycloalkyl, -(CH₂)_qC(=O)NHalkyl, -(CH₂)_qC(=O)N(alkyl)₂, -(CH₂)_qC(=O)NHalkylaryl, -(CH₂)_qC(=O)NHaryl, -(CH₂)_qC(=O)NHaralkyl, -
 15 (CH₂)_qC(=O)NHcycloalkyl, -(CH₂)_qSO₂alkyl, -(CH₂)_qSO₂alkylaryl, -(CH₂)_qSO₂aryl, -(CH₂)_qSO₂aralkyl, -(CH₂)_qSO₂cycloalkyl, -(CH₂)_qNSO₂alkyl, -(CH₂)_qNSO₂alkylaryl, -(CH₂)_qNSO₂aryl, -(CH₂)_qNSO₂aralkyl, -(CH₂)_qNSO₂cycloalkyl, -(CH₂)_qSO₂NHalkyl, -(CH₂)_qSO₂NHalkylaryl, -(CH₂)_qSO₂NHaryl, -(CH₂)_qSO₂NHaralkyl, -(CH₂)_qSO₂NHcycloalkyl,
 20 heterocyclenyl, heterocyclyl, and heteroaryl;

the R^{31} moieties can be the same or different, each being independently selected from the group consisting of alkyl, alkylaryl, aryl, aralkyl, cycloalkyl, -(CH₂)_qOH, -(CH₂)_qOalkyl, -(CH₂)_qOalkylaryl, -(CH₂)_qOaryl, -(CH₂)_qOaralkyl, -(CH₂)_qOcycloalkyl, -(CH₂)_qNH₂, -(CH₂)_qNHalkyl, -
 25 (CH₂)_qN(alkyl)₂, -(CH₂)_qNHalkylaryl, -(CH₂)_qNHaryl, -(CH₂)_qNHaralkyl, -(CH₂)_qNHcycloalkyl, -(CH₂)_qC(=O)NHalkyl, -(CH₂)_qC(=O)N(alkyl)₂, -(CH₂)_qC(=O)NHalkylaryl, -(CH₂)_qC(=O)NHaryl, -(CH₂)_qC(=O)NHaralkyl, -(CH₂)_qC(=O)NHcycloalkyl, -(CH₂)_qSO₂alkyl, -(CH₂)_qSO₂alkylaryl, -(CH₂)_qSO₂aryl, -(CH₂)_qSO₂aralkyl, -(CH₂)_qSO₂cycloalkyl, -(CH₂)_qNSO₂alkyl, -
 30 (CH₂)_qNSO₂alkylaryl, -(CH₂)_qNSO₂aryl, -(CH₂)_qNSO₂aralkyl, -(CH₂)_qNSO₂cycloalkyl, -(CH₂)_qSO₂NHalkyl, -(CH₂)_qSO₂NHalkylaryl, -(CH₂)_qSO₂NHaryl, -(CH₂)_qSO₂NHaralkyl, -(CH₂)_qSO₂NHcycloalkyl, heterocyclenyl, heterocyclyl, and heteroaryl;

m is 0 to 4;

n is 0 to 4;

p is 0 to 5;

each q can be the same or different, each being independently selected from 1 to 5; and

5 r is 1 to 4;

with the proviso that there are no two adjacent double bonds in any ring, and that when a nitrogen is substituted by two alkyl groups, said two alkyl groups may be optionally joined to each other to form a ring.

A further feature of the invention is a pharmaceutical composition
10 containing as active ingredient at least one compound of Formula 1 together with at least one pharmaceutically acceptable carrier or excipient.

The invention provides methods of preparing compounds of Formula 1, as well as methods for treating diseases, for example, treatment (e. g., palliative therapy, curative therapy, prophylactic therapy) of certain diseases
15 and conditions e. g., inflammatory diseases (e. g., psoriasis), autoimmune diseases (e. g., rheumatoid arthritis, multiple sclerosis), graft rejection (e. g., allograft rejection, xenograft rejection), infectious diseases and tumors. The invention provides a method of treating a CXCR3 chemokine mediated disease in a patient in need of such treatment comprising administering to the
20 patient a therapeutically effective amount of at least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

The invention provides methods of treating diseases, for example, treatment (e. g., palliative therapy, curative therapy, prophylactic therapy) of certain diseases and conditions such as inflammatory diseases (e. g.,
25 psoriasis, inflammatory bowel disease), autoimmune diseases (e. g., rheumatoid arthritis, multiple sclerosis), graft rejection (e. g., allograft rejection, xenograft rejection), infectious diseases as well as cancers and tumors, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation or dry eye, type I diabetes, viral
30 meningitis and tuberculoid leprosy comprising administering: (a) a therapeutically effective amount of at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one medicament selected from the group consisting of: disease modifying antirheumatic drugs; nonsteroidal

anti-inflammatory drugs; COX-2 selective inhibitors; COX-1 inhibitors; immunosuppressives (such as cyclosporins and methotrexate); steroids (including corticosteroids such as glucocorticoids); PDE IV inhibitors, anti-TNF- α compounds, TNF- α -convertase (TACE) inhibitors, MMP inhibitors, cytokine
5 inhibitors, glucocorticoids, other chemokine inhibitors such as CCR2 and CCR5, CB2-selective inhibitors, p38 inhibitors, biological response modifiers; anti-inflammatory agents and therapeutics.

The invention also provides a method of modulating (inhibiting or promoting) an inflammatory response in an individual in need of such therapy.

10 The method comprises administering a therapeutically effective amount of a compound (e. g., small organic molecule) which inhibits or promotes mammalian CXCR3 function in an individual in need thereof. Also disclosed is a method of inhibiting or blocking T-cell mediated chemotaxis in a patient in need of such treatment comprising administering to the patient a
15 therapeutically effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof.

Also disclosed is a method of treating inflammatory bowel disease (such Crohn's disease, ulcerative colitis) in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at
20 least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

Also disclosed is a method of treating inflammatory bowel disease in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of: (a) at least one compound of Formula 1,
25 or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: sulfasalazine, 5-aminosalicylic acid, sulfapyridine, anti-TNF compounds, anti-IL-12 compounds, corticosteroids, glucocorticoids, T-cell receptor directed therapies (such as anti-CD3 antibodies),
30 immunosuppressives, methotrexate, azathioprine, and 6-mercaptopurines.

Also disclosed is a method of treating graft rejection in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

Also disclosed is a method of treating graft rejection in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of: (a) at least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: cyclosporine A, FK-506, FTY720, beta-interferon, rapamycin, mycophenolate, prednisolone, azathioprine, cyclophosphamide and an antilymphocyte globulin.

Also disclosed is a method of treating multiple sclerosis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: (a) a therapeutically effective amount of at least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: beta-interferon, glatiramer acetate, corticosteroids, glucocorticoids, methotrexate, azothioprine, mitoxantrone, VLA-4 inhibitors, FTY720, anti-IL-12 inhibitors, and CB2-selective inhibitors.

Also disclosed is a method of treating multiple sclerosis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: (a) a therapeutically effective amount of at least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: methotrexate, cyclosporin, leflunomide, sulfasalazine, corticosteroids, β -methasone, β -interferon, glatiramer acetate, prednisone, etanercept, and infliximab.

Also disclosed is a method of treating rheumatoid arthritis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: (a) at least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: non-steroidal anti-inflammatory agents, COX-2 inhibitors, COX-1 inhibitors, immunosuppressives, cyclosporine, methotrexate, steroids, PDE IV inhibitors, anti-TNF- α compounds, MMP inhibitors, corticosteroids, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, caspase (ICE)

inhibitors and other classes of compounds indicated for the treatment of rheumatoid arthritis.

Also disclosed is a method of treating psoriasis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: a) at least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: immunosuppressives, cyclosporins, methotrexate, steroids, corticosteroids, anti-TNF- α compounds, anti-IL compounds, anti-IL-23 compounds, vitamin A and D compounds and fumarates.

Also disclosed is a method of treating ophthalmic inflammation (including, for e.g., uveitis, posterior segment intraocular inflammation, Sjogren's syndrome) or dry eye in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: a) at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: immunosuppressives, cyclosporins, methotrexate, FK506, steroids, corticosteroids, and anti-TNF- α compounds.

Also disclosed is a method of treating a disease selected from the group consisting of: inflammatory disease, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, graft rejection, psoriasis, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation (including e.g., uveitis, posterior segment intraocular inflammation, and Sjogren's syndrome), tuberculoid leprosy and cancer in a patient in need of such treatment, such method comprising administering to the patient an effective amount of at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

The invention also provides a method of treating a disease selected from the group consisting of: inflammatory disease, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, graft rejection, psoriasis, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses and tuberculoid leprosy, ophthalmic inflammation, type I diabetes, viral meningitis and cancer in a patient in need of such treatment, such method comprising

administering to the patient an effective amount of (a) at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one medicament selected from the group consisting of: disease modifying antirheumatic drugs; nonsteroidal antiinflammatory drugs; COX-2 selective inhibitors; COX-1 inhibitors; immunosuppressives; steroids; PDE IV inhibitors, anti-TNF- α compounds, MMP inhibitors, corticosteroids, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, biological response modifiers; anti-inflammatory agents and therapeutics.

DETAILED DESCRIPTION OF THE INVENTION

The terms used herein have their ordinary meaning and the meaning of such terms is independent at each occurrence thereof. That notwithstanding and except where stated otherwise, the following definitions apply throughout the specification and claims. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of "alkyl" applies to "alkyl" as well as the "alkyl" portions of "hydroxyalkyl," "haloalkyl," "alkoxy," etc.

As used above, and throughout the specification, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

"Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. The alkenyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, cycloalkyl,

cycloalkenyl, cyano, heteroaryl, heterocyclyl, heterocyclenyl, amino, aminosulfonyl, halo, carboxyl, carboxyalkyl (non-limiting example(s) include ester), alkoxycarbonyl, hydroxyalkyl, carbonyl (non-limiting example(s) include ketone), -C(=O)heterocyclyl, formyl (non-limiting example(s) include aldehyde), carboxamido (i.e. amido, -C(=O)NH₂), -C(=O)N(alkyl)₂, -C(=O)NH(alkyl), -C(=O)N(cycloalkyl)₂, -C(=O)NH(cycloalkyl), -NHC(=O)alkyl, urea (e.g. -NH(C=O)NH₂, -NH(C=O)NH(alkyl), -NH(C=O)NH(alkyl)₂, -NH(C=O)NH(heteroaryl), -NH(C=O)NH(heterocyclyl)), guanidiny, -NHC(=NCN)NH₂, -NHC(=NCN)N(alkyl)₂, carbamoyl (i.e. -CO₂NH₂), NHC(=O)Oalkyl, -CO₂N(alkyl)₂, -NHC(=O))NH-S(O)₂alkyl, -NHC(=O)N(alkyl)₂-S(O)₂alkyl, -NH-S(O)₂alkyl, -NH-S(O)₂heteroaryl, -N(alkyl)-S(O)₂alkyl, -NH-S(O)₂aryl, -N(alkyl)-S(O)₂aryl, -NH-S(O)₂NH₂, -NH-S(O)₂NHalkyl, -NH-S(O)₂N(alkyl)₂, alkylthiocarboxy, -S(O)₂alkyl, -S(O)₂aryl, -OS(O)₂alkyl, -OS(O)₂aryl, sulfonyl urea (non-limiting example(s) include NHC(=S)NHalkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.

"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain.

Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain.

More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl" means a group having about 1 to about 6 carbon atoms in the chain which may be

straight or branched. The alkyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, cycloalkyl, cycloalkenyl, cyano, heteroaryl, heterocyclyl, heterocyclenyl, amino, -NH(alkyl), -N(alkyl)₂, -NH(cycloalkyl), -N(cycloalkyl)₂, -NH(aryl), -N(aryl)₂, -NH(heteroaryl), -N(heteroaryl)₂, -NH(heterocyclyl), N(heterocyclyl)₂, halo, hydroxy, carboxyl, carboxyalkyl (non-limiting example(s) include ester), alkoxycarbonyl, hydroxyalkyl, carbonyl (non-limiting example(s) include ketone), -C(=O)heterocyclyl, formyl, carboxamido (i.e. amido, -C(=O)NH₂, -C(=O)N(alkyl)₂, -C(=O)NH(alkyl), -C(=O)N(cycloalkyl)₂,

-C(=O)NH(cycloalkyl), -NHC(=O)alkyl, amidinyl, hydrazidyl, hydroxamate, -NHC(=O)H, -NHC(=O)alkyl, urea (non-limiting example(s) include -NH(C=O)NH₂, -NH(C=O)NH(alkyl), -NH(C=O)N(alkyl)₂, -NH(C=O)NH(heteroaryl), -NH(C=O)NH(heterocyclyl), guanidinyl, 5 -NHC(=NCN)NH₂, -NHC(=NCN)N(alkyl)₂, carbamoyl (i.e., -CO₂NH₂), -NHC(=O)Oalkyl, -CO₂N(alkyl)₂, -NHC(=O)NH-S(O)₂alkyl, -NHC(=O)N(alkyl)-S(O)₂alkyl, -NH-S(O)₂alkyl, -NH-S(O)₂heteroaryl, -N(alkyl)-S(O)₂alkyl, -NH-S(O)₂aryl, -N(alkyl)-S(O)₂aryl, -NH-S(O)₂NH₂, -NH-S(O)₂NHalkyl, -NH-S(O)₂N(alkyl)₂, thio, alkylthio, alkylthiocarboxy, 10 -S(O)alkyl, -S(O)₂alkyl, -S(O)₂aryl, -OS(O)₂alkyl, -OS(O)₂aryl, sulfonyl urea (non-limiting example(s) include -NHC(=S)NHalkyl) and OSi(alkyl)₃. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, heptyl, nonyl, decyl, fluoromethyl, trifluoromethyl and cyclopropylmethyl.

15 "Alkylheteroaryl" means an alkyl-heteroaryl- group wherein the alkyl is as previously described and the bond to the parent moiety is through the heteroaryl group.

"Alkylamino" means an -NH₂ or -NH₃⁺ group in which one or more of the hydrogen atoms on the nitrogen is replaced by an alkyl group as defined 20 above. The bond to the parent is through the nitrogen.

"Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as described herein. Preferred alkylaryls comprise a lower alkyl group. Non-limiting examples of suitable alkylaryl groups include o-tolyl, p-tolyl and xylyl. The bond to the parent moiety is through the aryl.

25 "Alkylthio" means an alkyl-S- group in which the alkyl group is as described herein. Non-limiting examples of suitable alkylthio groups include methylthio, ethylthio, i-propylthio and heptylthio. The bond to the parent moiety is through the sulfur.

"Alkylthiocarboxy" means an alkyl-S-C(=O)O- group. Preferred groups 30 are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the carboxy.

"Alkylsulfonyl" means an alkyl-S(O)₂- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.

"Alkylsulfinyl" means an alkyl-S(O)- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfinyl.

"Alkynyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butylnyl, 3-methylbutynyl, n-pentylnyl, and decynyl. The alkynyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, cycloalkyl, cycloalkenyl, cyano, heteroaryl, heterocyclyl, heterocyclenyl, -NH(alkyl), -N(alkyl)₂, -NH(cycloalkyl), -N(cycloalkyl)₂, -NH(aryl), -N(aryl)₂, -NH(heteroaryl), -N(heteroaryl)₂, -NH(heterocyclyl), N(heterocyclyl)₂, alkoxycarbonyl, hydroxyalkyl, carbonyl (non-limiting example(s) include ketone), -C(=O)heterocyclyl, carboxamido (i.e. amido, -C(=O)NH₂), -C(=O)N(alkyl)₂, -C(=O)NH(alkyl), -C(=O)N(cycloalkyl)₂, -C(=O)NH(cycloalkyl), alkylC(=O)NH-, -NHC(=O)alkyl, urea (e.g. -NH(C=O)NH₂), -NH(C=O)NH(alkyl), -NH(C=O)NH(alkyl)₂, -NH(C=O)NH(heteroaryl), -NH(C=O)NH(heterocyclyl), -S(O)₂alkyl, and -S(O)₂aryl.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, heptoxy and methylhydroxy. The bond to the parent moiety is through the ether oxygen.

"Alkoxycarbonyl" means an alkyl-O-C(=O)- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.

"Aminoalkyl" means an amine-alkyl- group in which alkyl is as previously defined. Preferred aminoalkyls contain lower alkyl. Non-limiting

examples of suitable aminoalkyl groups include aminomethyl and 2-Dimethylamino-2-ethyl. The bond to the parent moiety is through the alkyl.

"AmidinyI" means -C(=NR)NHR group. The R groups are defined as H, alkyl, alkylaryl, heteroaryl, hydroxyl, alkoxy, amino, ester, CN,
5 $\text{-NHSO}_2\text{alkyl}$, $\text{-NHSO}_2\text{Aryl}$, -NHC(=O)NHalkyl , and -NHalkyl . The bond to the parent moiety is through the carbon.

"Aralkyl" or "arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group attached to the aryl group. Non-limiting examples of suitable aralkyl
10 groups include phenylmethylene, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.

"Aralkenyl" means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Preferred aralkenyls contain a lower alkenyl group. Non-limiting examples of suitable aralkenyl groups include
15 2-phenethenyl and 2-naphthylethenyl. The bond to the parent moiety is through the alkenyl.

"Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.

20 "Aralkoxy" means an aralkyl-O- group in which the aralkyl group is as described above. The bond to the parent moiety is through the oxygen group.

"Aralkoxycarbonyl" means an aralkyl-O-C(=O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.

25 "Aroyl" means an aryl-C(=O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1- and 2-naphthoyl.

"Aryl" (sometimes abbreviated "Ar") means an aromatic monocyclic or
30 multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.

"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.

5 "Aryloxycarbonyl" means an aryl-O-C(=O)- group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.

"Arylsulfonyl" means an aryl-S(O)₂- group. The bond to the parent moiety is through the sulfonyl.


10 "Arylsulfinyl" means an aryl-S(O)- group. The bond to the parent moiety is through the sulfinyl.

"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through
15 the sulfur.

"Carboxyalkyl" means an alkyl-C(=O)O- group. The bond to the parent moiety is through the carboxy.

"Carboxamido" means -C(=O)NRR wherein R is H, alkyl, amino, aryl, cycloalkyl, heterocyclenyl, heteroaryl and carboxamido. The bond to the
20 parent moiety is through the carboxy.

Carbamates and urea substituents refer to groups with oxygens and nitrogens respectively adjacent an amide; representative carbamate and urea substituents include the following:



25 "Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined

above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples can include bicyclic cycloalkyls such as bicycloheptane.

Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalin,
5 norbornyl, adamantyl and the like.

"Cycloalkenyl" means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contains at least one carbon-carbon double bond.

Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. The
10 cycloalkenyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.

Non-limiting examples of suitable monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cycloheptenyl, and the like. Non-limiting example of a suitable multicyclic cycloalkenyl is norbornylenyl. The term

15 "cycloalkenyl" additionally means moieties such as cyclobutenedione, cyclopentenone, cyclopentenedione and the like.

"Halogen" (or halo) means fluorine, chlorine, bromine, or iodine.

Preferred are fluorine, chlorine and bromine.

"Haloalkyl" means an alkyl as defined above wherein one or more
20 hydrogen atoms on the alkyl is replaced by a halo group defined above.

"Heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination.

25 Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl" can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. The nitrogen or sulfur
30 atom of the heteroaryl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. . Non-limiting examples of suitable

heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyridazinyl, quinoxaliny, phthalazinyl,

imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like.

5 "Heterocyclyl" (or heterocycloalkyl) means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent
10 oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be
15 the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, oxazolidinyl, imidazolidinyl, thiomorpholinyl, thiazolidinyl, 1,3-dioxolanyl,
20 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

"Heterocyclenyl" means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is
25 an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the
30 heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide,

S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic azaheterocyclenyl groups include 1,2,3,4- tetrahydropyridine, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridine, 1,4,5,6-tetrahydropyrimidine, dihydro-2-pyrrolinyl, dihydro-3-pyrrolinyl, 5 dihydro-2-imidazolynyl, dihydro-2-pyrazolynyl, dihydro-4,5-triazolyl and the like. Non-limiting examples of suitable oxaheterocyclenyl groups include 3,4-dihydro-2H-pyran, dihydrofuranyl, fluorodihydrofuranyl, and the like. Non-limiting example of a suitable multicyclic oxaheterocyclenyl group is 7-oxabicyclo[2.2.1]heptenyl. Non-limiting examples of suitable monocyclic 10 thiaheterocyclenyl rings include thiophenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like.

"Heteroaralkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include 15 pyridylmethyl, 2-(furan-3-yl)ethyl and quinolin-(3-yl)methyl. The bond to the parent moiety is through the alkyl.

"Heteroaralkenyl" means an heteroaryl-alkenyl- group in which the heteroaryl and alkenyl are as previously described. Preferred heteroaralkenyls contain a lower alkenyl group. Non-limiting examples of 20 suitable heteroaralkenyl groups include 2-(pyrid-3-yl)ethenyl and 2-(quinolin-3-yl)ethenyl. The bond to the parent moiety is through the alkenyl.

"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.


25 The bond to the parent moiety is through the alkyl.

"Hydroxamate" means an alkyl-C(=O)NH-O- group. The bond to the parent moiety is through the oxygen group.

"Spiroalkyl" means an alkylene group wherein two carbon atoms of an alkyl group are attached to one carbon atom of a parent molecular group 30 thereby forming a carbocyclic or heterocyclic ring of three to eleven atoms.

Representative structures include examples such as:

The spiroalkyl groups of this invention:



can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined herein.


"Ring system substituent" means a substituent attached to an aromatic

5 or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, aryl, aroyl, aryloxy, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, heterocyclenyl, alkylaryl, alkylheteroaryl, aralkyl, aralkenyl, aralkoxy, aralkoxycarbonyl, amino, -NH(alkyl), -N(alkyl)₂, -NH(cycloalkyl), -N(cycloalkyl)₂, -NH(aryl), -N(aryl)₂, -NH(heteroaryl), -N(heteroaryl)₂, -NH(heterocyclyl), N(heterocyclyl)₂, halo, hydroxy, carboxyl, carboxyalkyl (non-limiting example(s) include ester), cyano, alkoxy carbonyl, hydroxyalkyl, carbonyl (non-limiting example(s) include ketone),
 15 -C(=O)heterocyclyl, formyl (non-limiting example(s) include aldehyde), carboxamido (i.e. amido, -C(=O)NH₂), -C(=O)N(alkyl)₂, -C(=O)NH(alkyl), -C(=O)N(cycloalkyl)₂, -C(=O)NH(cycloalkyl), alkylC(=O)NH-, -amidino, hydrazido, hydroxamate, -NHC(=O)H, -NHC(=O)alkyl, urea (e.g. -NH(C(=O)NH₂), -NH(C(=O)NH(alkyl)), -NH(C(=O)NH(alkyl))₂, -NH(C(=O)NH(heteroaryl)), -NH(C(=O)NH(heterocyclyl)), guanidinyl, -NHC(=NCN)NH₂, -NHC(=NCN)N(alkyl)₂, carbamoyl (i.e. -CO₂NH₂), NHC(=O)Oalkyl, -CO₂N(alkyl)₂, -NHC(=O))NH-S(O)₂alkyl, -NHC(=O)N(alkyl)₂-S(O)₂alkyl, -NH-S(O)₂alkyl, -NH-S(O)₂heteroaryl, -N(alkyl)-S(O)₂alkyl, -NH-S(O)₂aryl, -N(alkyl)-S(O)₂aryl, -NH-S(O)₂NH₂,
 20 -NH-S(O)₂NHalkyl, -NH-S(O)₂N(alkyl)₂, thio, alkylthiocarboxy, -S(O)₂alkyl, -S(O)₂aryl, -OS(O)₂alkyl, -OS(O)₂aryl, sulfonyl urea (non-limiting example(s) include -NHC(=S)NHalkyl) and OSi(alkyl)₃.

"Ring system substituent" also means a cyclic ring of 3 to 7 ring atoms of which may contain 1 or 2 heteroatoms, attached to an aryl, heteroaryl,
 30 heterocyclyl or heterocyclenyl ring by simultaneously substituting two ring

hydrogen atoms on said aryl, heteroaryl, heterocyclyl or heterocyclenyl ring.

Non-limiting examples include:



and the like.


The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties, in available position or positions.

With reference to the number of moieties (non-limiting example(s) include, substituents, groups or rings) in a compound, unless otherwise defined, the phrases "one or more" and "at least one" mean that, there can be as many moieties as chemically permitted, and the determination of the maximum number of such moieties is well within the knowledge of those skilled in the art. Preferably, there are one to three substituents, or more preferably, one to two substituents, with at least one in the para position.


As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

The straight line — as a bond generally indicates a mixture of, or either of, the possible isomers, non-limiting example(s) include, containing

(R)- and (S)- stereochemistry. For example,



Lines drawn into the ring systems, such as, for example:



indicate that the indicated line (bond) may be attached to any of the substitutable ring carbon atoms.

As well known in the art, a bond drawn from a particular atom wherein no moiety is depicted at the terminal end of the bond indicates a methyl group bound through that bond to the atom, unless stated otherwise. For example:



It should also be noted that any heteroatom with unsatisfied valences in the text, schemes, examples, structural formulae, and any Tables herein is assumed to have the hydrogen atom or atoms to satisfy the valences.

Prodrugs and solvates of the compounds of the invention are also contemplated herein. The term "prodrug", as employed herein, denotes a compound that is a drug precursor which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of Formula 1 or a salt and/or solvate thereof. A discussion of prodrugs is provided in T. Higuchi and V. Stella, *Pro-drugs as Novel Delivery Systems* (1987) Volume 14 of the A.C.S. Symposium Series, and in *Bioreversible Carriers in Drug Design*, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, both of which are incorporated herein by reference thereto.

Metabolic conjugates, for example, glucoronides and sulfates which can under reversible conversion to compounds of Formula 1 are contemplated in this application.

"Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective to antagonize CXCR3 and thus produce the desired therapeutic effect in a suitable patient.

"Mammal" means humans and other mammalian animals.

"Patient" includes both human and animals.

"Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding.

In certain instances the solvate will be capable of isolation, for example when

one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent
5 molecule is H₂O.

The compounds of Formula 1 form salts which are also within the scope of this invention. Reference to a compound of Formula 1 herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with
10 inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula 1 contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used
15 herein. Pharmaceutically acceptable (non-limiting example(s) include, non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula 1 may be formed, for example, by reacting a compound of Formula 1 with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the
20 salt precipitates or in an aqueous medium followed by lyophilization. Acids (and bases) which are generally considered suitable for the formation of pharmaceutically useful salts from basic (or acidic) pharmaceutical compounds are discussed, for example, by S. Berge *et al*, *Journal of Pharmaceutical Sciences* (1977) 66(1) 1-19; P. Gould, *International J. of Pharmaceutics* (1986) 33 201-217; Anderson *et al*, *The Practice of Medicinal Chemistry* (1996), Academic Press, New York; in *The Orange Book* (Food & Drug Administration, Washington, D.C. on their website); and P. Heinrich Stahl, Camille G. Wermuth (Eds.), *Handbook of Pharmaceutical Salts: Properties, Selection, and Use*, (2002) Int'l. Union of Pure and Applied
25 Chemistry, pp. 330-331. These disclosures are incorporated herein by reference thereto.

Exemplary acid addition salts include acetates, adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates,

cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates, methanesulfonates, methyl sulfates, 2-naphthalenesulfonates, nicotines, nitrates, oxalates, pamoates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates, sulfonates (such as those mentioned herein), tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) undecanoates, and the like.

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, aluminum salts, zinc salts, salts with organic bases (for example, organic amines) such as benzathines, diethylamine, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, piperazine, phenylcyclohexylamine, choline, tromethamine, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (non-limiting example(s) include methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (non-limiting example(s) include dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (non-limiting example(s) include decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (non-limiting example(s) include benzyl and phenethyl bromides), and others.

All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example,

phenoxyethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C₁₋₄alkyl, or C₁₋₄alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and
5 (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C₁₋₂₀ alcohol or reactive derivative thereof, or by a 2,3-di (C₆₋₂₄)acyl glycerol.

Compounds of Formula 1, and salts, solvates and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether).
10 All such tautomeric forms are contemplated herein as part of the present invention.

All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs),
15 such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example,
20 be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the *IUPAC* 1974 Recommendations. The use of the terms "salt", "solvate" "prodrug" and the like, is intended to equally apply to the salt, solvate and
25 prodrug of enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrugs of the inventive compounds.

It should also be noted that throughout the specification and Claims appended hereto any formula, compound, moiety or chemical illustration with unsatisfied valences is assumed to have the hydrogen atom to satisfy the
30 valences unless the context indicates a bond.

In one embodiment, the present invention discloses compounds of Formula 1, having CXCR3 antagonist activity, or a pharmaceutically acceptable derivative thereof, where the various definitions are given above.

In another embodiment of the invention, wherein R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkyl, aryl, amino, alkoxy, halogen, hydroxy, cycloalkyl, alkyl-cycloalkyl-, cycloalkenyl, arylalkyl, amidinyl, carboxamido, heteroaryl, heterocyclyl, heterocyclenyl, urea, $-S(O)_2$ alkyl, $-S(O)_2N(H)$ alkyl, $-S(O)_2N(alkyl)_2$, and $-C(=S)N(H)$ cycloalkyl.


In another embodiment of the invention, R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkyl, aryl, amino, alkoxy, halogen, hydroxy, cycloalkyl, cycloalkenyl, arylalkyl, amidinyl, carboxamido, heteroaryl, heterocyclyl, heterocyclenyl, urea, $-S(O)_2$ alkyl, $-S(O)_2N(H)$ alkyl, $-S(O)_2N(alkyl)_2$, and $-C(=S)N(H)$ cycloalkyl.

In another embodiment of the invention, R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkylaryl, alkyl-cycloalkyl-, aryl, heteroaryl, $-(CH_2)_qCF_3$, $-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNHSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-(CH_2)_q$ -amidinyl, cyclopropyl, cyclopropylhydroxyl, cyclobutyl, cyclobutylhydroxy, cyclopentyl, and cyclopentylhydroxy; and q is an integer from 1 to 5.


In another embodiment of the invention, R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkylaryl, aryl, heteroaryl, $-(CH_2)_qCF_3$, $-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNHSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-(CH_2)_q$ -amidinyl, cyclopropyl, cyclopropylhydroxyl, cyclobutyl, cyclobutylhydroxy, cyclopentyl, and cyclopentylhydroxy; and q is an integer from 1 to 5.

In another embodiment of the invention, R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, $-CH_3$, fluorophenylmethylene, trifluoromethylphenylmethylene, indanyl, cyanophenylmethylene, difluorophenylmethylene, bromophenylmethylene, chlorophenylmethylene, $-CH_2CH_2O$ phenyl, cyclopentyl, bromochlorophenylmethylene, fluorochlorophenylmethylene,


- dichlorophenylmethylene, phenylmethylene, $-(CH_2)_3$ phenyl, $-CH_2CF_3$,
 methoxyphenylmethylene, $-CH(CH_3)_2$, $-C_2H_5$, $-CH_2$ -cyclopropyl, $-(CH_2)_2CH_3$,
 cyclohexylmethylene, cyclohexyl, $-CH_2CH_2SO_2CH_3$, $-CH_2-CH_2-NH_2$,
 $-CH_2CH_2OCH_3$, cyclopropyl, CH_3 -cyclopropyl, isoxazolyl, $-CH_2CH_2OH$,
 5
 $-CH_2CH_2O$ phenyl, $-CH_2CH_2CH_3$, $-NH_2$, $-(CH_2)_2NH_2$, pyrazolyl,
 5-methyl-isoxazolyl, $-CH_2CH(OCH_2CH_3)_2$, $-OCH_3$, $-NHC(=O)NH_2$,
 chloropyridyl, pyridylmethylene, $-C(=O)NH$ cyclopropyl, $-C(=O)N(H)C_2H_5$,
 $-C(=O)N(H)CH_2CF_3$, $-C(=O)N(H)C(CH_3)_3$, $-C(=S)N(H)$ cyclopropyl,
 $-C(=O)NH_2$, $-C(=O)N(H)CH_3$, $-S(O)_2CH_3$, $-S(O)_2N(CH_3)_2$, $-S(O)_2CH_2CH_3$,
 10
 $-C(=O)CH_3$, $-S(O)_2(CH_2)_2CH_3$, $-C(=O)N(H)$ cyclohexyl, $-C(=NH)NH_2$,
 $-C(=O)N(H)NH_2$, $-C(=O)N(H)CH(CH_3)_2$, thiazolyl, $-C(=O)N(CH_3)_2$,
 $-S(O)_2CH_2CF_3$, cyclopropyl, $-S(O)_2CF_3$, $-CH_2CH(OCH_2CH_3)_2$,




15




38




- In another embodiment of the invention, R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, $-\text{CH}_3$, fluorophenylmethylene, trifluoromethylphenylmethylene, indanyl, cyanophenylmethylene, difluorophenylmethylene, bromophenylmethylene, chlorophenylmethylene, $-\text{CH}_2\text{CH}_2\text{Ophenyl}$, cyclopentyl, bromochlorophenylmethylene, fluorochlorophenylmethylene, dichlorophenylmethylene, phenylmethylene, $-(\text{CH}_2)_3\text{phenyl}$, $-\text{CH}_2\text{CF}_3$, methoxyphenylmethylene, $-\text{CH}(\text{CH}_3)_2$, $-\text{C}_2\text{H}_5$, $-\text{CH}_2\text{-cyclopropyl}$, $-(\text{CH}_2)_2\text{CH}_3$, cyclohexylmethylene, cyclohexyl, $-\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-NH}_2$, $-\text{CH}_2\text{CH}_2\text{OCH}_3$, cyclopropyl, isoxazolyl, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{Ophenyl}$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{NH}_2$, $-(\text{CH}_2)_2\text{NH}_2$, pyrazolyl, 5-methyl-isoxazolyl, $-\text{CH}_2\text{CH}(\text{OCH}_2\text{CH}_3)_2$, $-\text{OCH}_3$, $-\text{NHC}(=\text{O})\text{NH}_2$, chloropyridyl, pyridylmethylene, $-\text{C}(=\text{O})\text{NHcyclopropyl}$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{C}_2\text{H}_5$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{CH}_2\text{CF}_3$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{C}(\text{CH}_3)_3$, $-\text{C}(=\text{S})\text{N}(\text{H})\text{cyclopropyl}$, $-\text{C}(=\text{O})\text{NH}_2$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{CH}_3$, $-\text{S}(\text{O})_2\text{CH}_3$, $-\text{S}(\text{O})_2\text{N}(\text{CH}_3)_2$, $-\text{S}(\text{O})_2\text{CH}_2\text{CH}_3$, $-\text{C}(=\text{O})\text{CH}_3$, $-\text{S}(\text{O})_2(\text{CH}_2)_2\text{CH}_3$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{cyclohexyl}$, $-\text{C}(=\text{NH})\text{NH}_2$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{NH}_2$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{CH}(\text{CH}_3)_2$, thiazolyl, $-\text{C}(=\text{O})\text{N}(\text{CH}_3)_2$, $-\text{S}(\text{O})_2\text{CH}_2\text{CF}_3$, cyclopropyl, $-\text{S}(\text{O})_2\text{CF}_3$, $-\text{CH}_2\text{CH}(\text{OCH}_2\text{CH}_3)_2$,




20






40



or when X is N, the N taken together with the R¹ and R² to which X is shown
 10 attached, forms a -N-cyclopropyl, -N-cyclobutyl, -N-cyclohexyl or




In another embodiment of the invention, R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$, difluorophenylmethylene, cyclopropyl, CH_3 -cyclopropyl-, dichlorophenylmethylene, $-CH(CH_3)_2$, cyclohexylmethylene, cyclohexyl, isoxazolyl, oxadiazolyl, aminooxadiazolyl, substituted isooxazolyl, substituted oxadiazolyl, substituted aminooxadiazolyl, difluorophenyl, $-CH_2CH_2OH$, $-CH_2CH_2N(CH_3)_2$, $-C(=O)N(H)cyclopropyl$, $-C(=O)N(H)C_2H_5$, $-C(=O)N(H)CH_2CF_3$, $-C(=O)N(H)CH(CH_3)_2$, $-C(=O)N(H)C(CH_3)_3$, $-C(=S)N(H)cyclopropyl$, $-C(=O)NH_2$, $-C(=O)N(H)CH_3$, $-S(O)_2CH_3$, $-S(O)_2N(CH_3)_2$, $-S(O)_2CH_2CH_3$, $-C(=O)CH_3$, $-S(O)_2(CH_2)_2CH_3$, $-C(=O)N(H)cyclohexyl$, $-C(=NH)NH_2$, $-C(=O)N(H)NH_2$, thiazolyl,




In another embodiment of the invention, R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$, difluorophenylmethylene, cyclopropyl, dichlorophenylmethylene, $-CH(CH_3)_2$, cyclohexylmethylene, cyclohexyl,


- isoxazolyl, difluorophenyl, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$,
 $-\text{C}(=\text{O})\text{N}(\text{H})\text{cyclopropyl}$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{C}_2\text{H}_5$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{CH}_2\text{CF}_3$,
 $-\text{C}(=\text{O})\text{N}(\text{H})\text{CH}(\text{CH}_3)_2$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{C}(\text{CH}_3)_3$, $-\text{C}(=\text{S})\text{N}(\text{H})\text{cyclopropyl}$,
 $-\text{C}(=\text{O})\text{NH}_2$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{CH}_3$, $-\text{S}(\text{O})_2\text{CH}_3$, $-\text{S}(\text{O})_2\text{N}(\text{CH}_3)_2$, $-\text{S}(\text{O})_2\text{CH}_2\text{CH}_3$,
 5 $-\text{C}(=\text{O})\text{CH}_3$, $-\text{S}(\text{O})_2(\text{CH}_2)_2\text{CH}_3$, $-\text{C}(=\text{O})\text{N}(\text{H})\text{cyclohexyl}$, $-\text{C}(=\text{NH})\text{NH}_2$,
 $-\text{C}(=\text{O})\text{N}(\text{H})\text{NH}_2$, thiazolyl,




10



In another embodiment of the invention, X is selected from the group consisting of N, O, $-\text{CH}_3$, $-\text{CH}_2-$, $-\text{CH}$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CN}$, $-\text{NH}_2$, cyclopropyl,



In another embodiment of the invention, X is selected from the group consisting of N, O, -CH₃, -CH₂-, -CH-, -CH₂CH₃, -CH₂CN, -NH₂, cyclopropyl,



In another embodiment of the invention, R³ is selected from the group consisting of H, alkyl, haloalkyl, hydroxyalkyl, halogen, -N(R³⁰)₂, -OR³⁰ and -CF₃.


In another embodiment of the invention, R³ is selected from the group consisting of H, -CH₃, -CH₂CH₃, cyclopropyl, -F, -Cl, OCH₃, OCF₃ and CF₃.

In another embodiment of the invention, R⁶ is selected from the group consisting of H, alkyl, halogen, hydroxyalkyl, -CN, -N(R³⁰)₂, -OR³⁰, -N=CH-alkyl, and -NR³⁰C(=O)alkyl.


In another embodiment of the invention, R⁶ is selected from the group consisting of H, -NH₂, -CH₃, -CN and -F.

In another embodiment of the invention, R⁷ and R⁸ are the same or different, each being independently selected from the group consisting of H, -(CH₂)_qOH, -(CH₂)_qOalkyl, -(CH₂)_qN(H)-alkyl, -(CH₂)_qN(H)-S(O)₂alkyl, and -(CH₂)_qN(H)-CO-N(H)alkyl; or alternatively R⁷ and R⁸ taken together is =O, =N(Oalkyl), or =S.

In another embodiment of the invention, R⁷ and R⁸ are the same or different, each being independently selected from the group consisting of H, -CH₃, and -OH; or alternatively R⁷ and R⁸ taken together with the carbon atom to which R⁷ and R⁸ are shown attached, is



In another embodiment of the invention, R^7 and R^8 are each H; or alternatively R^7 and R^8 taken together with the carbon atom to which R^7 and R^8 are shown attached, is



5 In another embodiment of the invention, R^{10} is selected from the group consisting of H, alkyl, aralkyl, hydroxyalkyl, and carbonyl.

In another embodiment of the invention, R^{10} is selected from the group consisting of $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$ and $-\text{CH}_2\text{CH}_2\text{CH}_3$, and m is 0 - 2.

10 In another embodiment of the invention, R^{11} is selected from the group consisting of H, alkyl, hydroxyalkyl and carbonyl.

In another embodiment of the invention, R^{11} is H or $-\text{CH}_3$.

In another embodiment of the invention, R^{12} is selected from the group consisting of H, CN, $-\text{C}(=\text{O})\text{N}(\text{R}^{30})_2$ and alkyl.

15 In another embodiment of the invention, R^{12} is selected from the group consisting of H, $-\text{CH}_3$, CN and $-\text{CH}_2\text{CH}_3$.

In another embodiment of the invention, the phenyl ring D is substituted by independently selected 1-4 R^{20} moieties.

20 In another embodiment of the invention, the R^{20} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylheteroaryl, alkylsulfinyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkoxy, aryl, aryloxy, cyano, cycloalkyl, cycloalkenyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxyalkyl, trifluoromethyl, trifluoromethoxy, -
 25 $(\text{CH}_2)_q\text{OR}^{31}$, $-(\text{CH}_2)_q\text{NHR}^{31}$, $-(\text{CH}_2)_q\text{C}(=\text{O})\text{NHR}^{31}$, $-(\text{CH}_2)_q\text{SO}_2\text{R}^{31}$, -
 $(\text{CH}_2)_q\text{NSO}_2\text{R}^{31}$, $-(\text{CH}_2)_q\text{SO}_2\text{NHR}^{31}$, $-\text{alkynylC}(\text{R}^{31})_2\text{OR}^{31}$, $-\text{C}(=\text{O})\text{R}^{30}$, -
 $\text{C}(=\text{O})\text{N}(\text{R}^{30})_2$, $-\text{C}(=\text{O})\text{OR}^{30}$, $-\text{N}(\text{R}^{30})_2$, $-\text{N}(\text{R}^{30})\text{C}(=\text{O})\text{R}^{31}$, $-\text{NHC}(=\text{O})\text{N}(\text{R}^{30})_2$,
 $-\text{N}(\text{R}^{30})\text{C}(=\text{O})\text{OR}^{31}$, $-\text{N}(\text{R}^{30})\text{C}(=\text{NCN})\text{N}(\text{R}^{30})_2$, $-\text{N}(\text{R}^{30})\text{C}(=\text{O})\text{N}(\text{R}^{30})_2$,
 $-\text{N}(\text{R}^{30})\text{SO}_2(\text{R}^{31})$, $-\text{N}(\text{R}^{30})\text{SO}_2\text{N}(\text{R}^{30})_2$, $-\text{OR}^{30}$, $-\text{OC}(=\text{O})\text{N}(\text{R}^{30})_2$, $-\text{SR}^{30}$,
 $-\text{SO}_2\text{N}(\text{R}^{30})_2$, $-\text{SO}_2(\text{R}^{31})$, $-\text{OSO}_2(\text{R}^{31})$, $-\text{O}(\text{CH}_2)_q\text{SO}_2\text{R}^{31}$, and $-\text{OSi}(\text{R}^{30})_3$.

30 In another embodiment of the invention, the R^{20} moieties can be the same or different, each being independently selected from the group

consisting of H, alkyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylheteroaryl, alkylsulfinyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkoxy, aryl, aryloxy, cyano, cycloalkyl, cycloalkenyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxyalkyl, trifluoromethyl, trifluoromethoxy, -

5 (CH₂)_qOR³¹, -(CH₂)_qNHR³¹, -(CH₂)_qC(=O)NHR³¹, -(CH₂)_qSO₂R³¹, - (CH₂)_qNSO₂R³¹, -(CH₂)_qSO₂NHR³¹, -alkynylC(R³¹)₂OR³¹, -C(=O)R³⁰, - C(=O)N(R³⁰)₂, -C(=O)OR³⁰, -N(R³⁰)₂, -N(R³⁰)C(=O)R³¹, -NHC(=O)N(R³⁰)₂, -N(R³⁰)C(=O)OR³¹, -N(R³⁰)C(=NCN)N(R³⁰)₂, -N(R³⁰)C(=O)N(R³⁰)₂, -N(R³⁰)SO₂(R³¹), -N(R³⁰)SO₂N(R³⁰)₂, -OR³⁰, -OC(=O)N(R³⁰)₂, -SR³⁰, -SO₂N(R³⁰)₂, -SO₂(R³¹), -OSO₂(R³¹), and -OSi(R³⁰)₃.

In another embodiment of the invention, the R²⁰ moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkoxy, amino, halogen, CN, CH₃, CF₃, OCH₃, OCF₃, -

15 (CH₂)_qOR³¹, -(CH₂)_qNHR³¹, -(CH₂)_qC(=O)NHR³¹, -(CH₂)_qSO₂R³¹, - (CH₂)_qNSO₂R³¹, -(CH₂)_qSO₂NHR³¹, -alkynylC(R³¹)₂OR³¹, -C(=O)R³⁰, -C(=O)OR³⁰, -N(R³⁰)₂, -N(R³⁰)C(=O)R³¹, -NHC(=O)N(R³⁰)₂, -N(R³⁰)C(=O)OR³¹, -N(R³⁰)C(=NCN)N(R³⁰)₂, -N(R³⁰)C(=O)N(R³⁰)₂, -OR³⁰, -OC(=O)N(R³⁰)₂, -O(CH₂)_qSO₂R³¹ and -OSO₂(R³¹).

In another embodiment of the invention, the R²⁰ moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, amino, halogen, CN, CH₃, CF₃, OCF₃, -(CH₂)_qOR³¹, -


20 (CH₂)_qNHR³¹, -(CH₂)_qC(=O)NHR³¹, -(CH₂)_qSO₂R³¹, -(CH₂)_qNSO₂R³¹, - (CH₂)_qSO₂NHR³¹, -alkynylC(R³¹)₂OR³¹, -C(=O)R³⁰, -C(=O)OR³⁰, -N(R³⁰)₂, -N(R³⁰)C(=O)R³¹, -NHC(=O)N(R³⁰)₂, -N(R³⁰)C(=O)OR³¹, -N(R³⁰)C(=NCN)N(R³⁰)₂, -N(R³⁰)C(=O)N(R³⁰)₂, -OR³⁰, -OC(=O)N(R³⁰)₂, and -OSO₂(R³¹).

In another embodiment of the invention, two R²⁰ moieties are linked together to form a five or six membered aryl, cycloalkyl, heterocyclenyl, heterocyclyl or heteroaryl ring wherein said five or six membered aryl, cycloalkyl, heterocyclenyl, heterocyclyl, and heteroaryl ring is fused to ring D

30 and the fused ring is optionally substituted with 0 to 4 R²¹ moieties.

In another embodiment of the invention, the R²⁰ moieties can be the same or different, each being independently selected from the group

consisting of H, -CN, -CH₃, -CF₃, -CH₂OH, -CO₂H, -CO₂CH₃, -NH₂, -NHCH₃, -OCF₃, -OH, F, Cl, Br, -C(=NOH)NH₂, -OCH₂CH₂S(O₂)CH₃, -C(=O)NH₂,



In another embodiment of the invention, Y is selected from the group consisting of: $-(\text{CHR}^{13})_r-$, $-(\text{CR}^{13}\text{R}^{13})_r-$, $-\text{C}(=\text{O})-$ and $-\text{CHR}^{13}\text{C}(=\text{O})-$.

In another embodiment of the invention, Y is selected from the group consisting of: $-\text{CH}_2-$, $-\text{CH}(\text{CH}_3)-$, $-\text{CH}(\text{CH}_2\text{OH})-$, $-\text{C}(=\text{O})-$ and $-\text{CH}(\text{CO}_2\text{alkyl})-$.

In another embodiment of the invention, m is 0-3.

In another embodiment of the invention, n is 0-2.

In another embodiment of the invention, q is 1, 2 or 3.

In another embodiment of the invention, p is 1, 2 or 3.

In another embodiment of the invention, r is 1 or 2.

In another embodiment of the invention,

X is N;

R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkylaryl, aryl, heteroaryl, $-(\text{CH}_2)_q\text{CF}_3$, $-(\text{CH}_2)_q\text{OH}$, $-(\text{CH}_2)_q\text{OR}^{31}$, $-(\text{CH}_2)_q\text{NH}_2$, $-(\text{CH}_2)_q\text{NHR}^{31}$, $-(\text{CH}_2)_q\text{N}(\text{R}^{31})_2$, $-(\text{CH}_2)_q\text{C}(=\text{O})\text{NHR}^{31}$, $-(\text{CH}_2)_q\text{SO}_2\text{R}^{31}$, $-(\text{CH}_2)_q\text{NHSO}_2\text{R}^{31}$, $-(\text{CH}_2)_q\text{SO}_2\text{NHR}^{31}$, $-(\text{CH}_2)_q$ -amidinyl, cyclopropyl, alkyl-cyclopropyl-, cyclopropylhydroxyl, cyclobutyl, cyclobutylhydroxy, cyclopentyl, and cyclopentylhydroxy;

R^3 is selected from the group consisting of H, alkyl, haloalkyl, hydroxyalkyl, halogen, $-\text{N}(\text{R}^{30})_2$, $-\text{OR}^{30}$ and $-\text{CF}_3$;

R^6 is selected from the group consisting of H, alkyl, halogen, hydroxyalkyl, -CN, $-\text{N}(\text{R}^{30})_2$, $-\text{OR}^{30}$, $-\text{N}=\text{CH}$ -alkyl, and $-\text{NR}^{30}\text{C}(=\text{O})\text{alkyl}$;


R^7 and R^8 are independently selected from the group consisting of $=\text{O}$, $=\text{S}$, $=\text{NH}$, $=\text{NOH}$, and $=\text{N}(\text{Oalkyl})$;

R^{10} is selected from the group consisting of H, alkyl, aralkyl, hydroxyalkyl, and carbonyl;

R^{11} is selected from the group consisting of H, alkyl, hydroxyalkyl, and carbonyl;

R^{12} is selected from the group consisting of H, CN, $-C(=O)N(R^{30})_2$ and alkyl;

the R^{20} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkoxy, amino, halogen, CN, CH_3 , CF_3 , OCH_3 , OCF_3 , $-(CH_2)_qOR^{31}$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, alkynyl $C(R^{31})_2OR^{31}$, $-C(=O)R^{30}$, $-C(=O)OR^{30}$, $-N(R^{30})_2$, $-N(R^{30})C(=O)R^{31}$, $-NHC(=O)N(R^{30})_2$, $-N(R^{30})C(=O)OR^{31}$, $-N(R^{30})C(=NCN)N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})_2$, $-OR^{30}$, $-OC(=O)N(R^{30})_2$,



Y is selected from the group consisting of: $-CH_2-$, $-CH(CH_3)-$, $-CH(CH_2OH)-$, $-C(=O)-$ and $-CH(CO_2alkyl)-$;

m is 0-2;

n is 0-2;

q is 1 or 2; and

r is 1 or 2.

In another embodiment of the invention,

X is N;

R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkylaryl, aryl, heteroaryl, $-(CH_2)_qCF_3$, $-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_q-N(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNHSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-(CH_2)_q$ -amidinyl, cyclopropyl, cyclopropylhydroxyl, cyclobutyl, cyclobutylhydroxy, cyclopentyl, and cyclopentylhydroxy;

R^3 is selected from the group consisting of H, alkyl, haloalkyl, hydroxyalkyl, halogen, $-N(R^{30})_2$, $-OR^{30}$ and $-CF_3$;

R^6 is selected from the group consisting of H, alkyl, halogen, hydroxyalkyl, $-CN$, $-N(R^{30})_2$, $-OR^{30}$, $-N=CH$ -alkyl, and $-NR^{30}C(=O)alkyl$;


R^7 and R^8 are independently selected from the group consisting of $=O$, $=S$, $=NH$, $=NOH$, and $=N(Oalkyl)$;

R^{10} is selected from the group consisting of H, alkyl, aralkyl, hydroxyalkyl, and carbonyl;

R^{11} is selected from the group consisting of H, alkyl, hydroxyalkyl, and carbonyl;

5 R^{12} is selected from the group consisting of H, CN, $-C(=O)N(R^{30})_2$ and alkyl;

the R^{20} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, amino, halogen, CN, CH_3 , CF_3 , OCF_3 , $-(CH_2)_qOR^{31}$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-alkynylC(R^{31})_2OR^{31}$, $-C(=O)R^{30}$, $-C(=O)OR^{30}$, $-N(R^{30})_2$, $-N(R^{30})C(=O)R^{31}$, $-NHC(=O)N(R^{30})_2$, $-N(R^{30})C(=O)OR^{31}$, $-N(R^{30})C(=NCN)N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})_2$, $-OR^{30}$, $-OC(=O)N(R^{30})_2$,



Y is selected from the group consisting of: $-CH_2-$, $-CH(CH_3)-$, $-CH(CH_2OH)-$, $-C(=O)-$ and $-CH(CO_2alkyl)-$;

m is 0-2;


n is 0-2;

20 p is 0 or 1;

q is 1 or 2; and

r is 1 or 2.





In another embodiment of the invention, the compound of Formula I is represented by the following structural Formula:

















wherein the various terms are as defined earlier.








In still another embodiment of the present invention, a compound is selected from the following structures in Table 1 below (or a pharmaceutically acceptable salt, solvate or ester thereof) which are shown along with their IC_{50} ratings. The IC_{50} values are rated, "A" for IC_{50} values less than about 25 nanomolar (nM), "B" for IC_{50} values in the range of from about 25 to about 100 nM and "C" for IC_{50} values greater than about 100 nM. For example, Compound No. 107 has an IC_{50} of 0.2 nM.








TABLE 1









Compound No.	Compound Structure	IC_{50}
1		A
2		A
3		A
4		A

5		A
6		A
7		A
8		A
9		A
10		A
11		A
12		A









13		A
14		A
15		A
16		A
17		A
18		A

19		A
20		A
21		A
22		A
23		B
24		B
25		B









26		B
27		B
28		B
29		B
30		B
31		B
32		B

33		B
34		B
35		B
36		B
37		B
38		B
39		B
40		B









55









41		B
42		C
43		C
44		C
45		C
46		C
47		C
48		C









56








49		C
50		C
51		C
52		C
53		C
54		C
55		C
56		C









57









57		C
58		C
59		C
60		C
61		A
62		A
63		A
64		A









65		A
66		A
67		A
68		A
69		A
70		A
71		B
72		B









73		B
74		B
75		B
76		C
77		C
78		C
79		C
80		C









81		C
82		A
83		A
84		A
85		A
86		A
87		A








88		A
89		A
90		A
91		A
92		A
93		A
94		B
95		B

96		C
97		C
98		C
99		A
100		A
101		B
102		A
103		A









104		B
105		C
106		C
107		A
108		A
109		A
110		A
111		A

112		A
113		A
114		A
115		A
116		A
117		A
118		A
119		A

120		A
121		A
122		A
123		A
124		A
125		A
126		A
127		A









128		A
129		A
130		A
131		A
132		A
133		A
134		A

67









135		A
136		A
137		A
138		A
139		A
140		A
141		A
142		A









143		A
144		A
145		A
146		A
147		A
148		A
149		A
150		A









151		A
152		A
153		A
154		A
155		A
156		A
157		A
158		A








159		A
160		A
161		A
162		A
163		A
164		A
165		A
166		A

71









167		A
168		A
169		A
170		A
171		A
172		A
173		A
174		A









175		A
176		A
177		B
178		B
179		B
180		B
181		B
182		B









183		B
184		B
185		B
186		B
187		B
188		B
189		B
190		B









191		B
192		C
193		C
194		C
195		C
196		C
197		C









75









198		C
199		C
200		C
201		C
202		C
203		C
204		C
205		C









206		C
207		C
208		C
209		C
210		C
211		C
212		C
213		B









214		A
215		A
216		A
217		A
218		A
219		A
220		A
221		A









222		A
223		A
224		B
225		C
226		C
227		B
228		A
229		A









230		A
231		A
232		B
233		A
234		B
235		C
236		C
237		C

238		A
239		A
240		A
241		A
242		B
243		A
244		A
245		A









246		A
247		B
248		B
249		B
250		B
251		C
252		B
253		B









254		B
255		B
256		A
257		A
258		A
259		A
260		A
261		B









262		C
263		C
264		A
265		A
266		A
267		A
268		A
269		C









270		A
271		A
272		B
273		C
274		C
275		C
276		C
277		A









85









278		A
279		A
280		C
281		C
282		B
283		C
284		A
285		A









286		A
287		C
288		C
289		C
290		A
291		B
292		A
293		C









294		A
295		A
296		A
297		B
298		B
299		B
300		C
301		C









302		C
303		C
304		A
305		C
306		C
307		C
308		C
309		C









310		C
311		C
312		C
313		C
314		A
315		A
316		A
317		A








318		B
319		B
320		B
321		B
322		B
323		B
324		C
325		C









326		C
327		C
328		C
329		C
330		A
331		A
332		A
333		A








334		A
335		A
336		A
337		A
338		A
339		A
340		A
341		B







342		B
343		B
344		B
345		B
346		B
347		B
348		B
349		B








350		B
351		B
352		C
353		C
354		C
355		C
356		C
357		C









358		C
359		C
360		C
361		C
362		C
363		C
364		C







365		C
366		C
367		C
368		C
369		C
370		A
371		A
372		C






373		C
374		C
375		B
376		B
377		B
378		A
379		C






380		C
381		B
382		C
383		C
384		C
385		A






386		A
387		A
388		A
389		A
390		A
391		A
392		A






393		A
394		A
395		A
396		A
397		A
398		A
399		A
400		A







401		A
402		A
403		A
404		B
405		C
406		C











407		C
408		B
409		A
410		A
411		A











412		A
413		A
414		A
415		A
416		A











417		A
418		A
419		A
420		A
421		A











422		A
423		B
424		C
425		C
426		C

427		C
428		C
429		C
430		C
431		A
432		A

433		A
434		A
435		A
436		A
437		A
438		A
439		A
440		A
441		A
442		A

453		A
454		A
455		A
456		A
457		A
458		A
459		A
460		A
461		A
462		A


463		A
464		A
465		A
466		A
467		A
468		A
469		A
470		A
471		A
472		A

473		A
474		A
475		A
476		A
477		A
478		A
479		A
480		A
481		A
482		A


483		A
484		A
485		A
486		A
487		A
488		A
489		A
490		A
491		A
492		A

or pharmaceutically acceptable salts, solvates or esters thereof.


In another aspect of the invention, the compound according to Formula 1 is selected from the group consisting of:




(0.3 nM)




(<1 nM)




(0.5 nM)




(0.5 nM)




(0.8 nM)




(0.8 nM)




(<1 nM)




(<1 nM)




(<1 nM)





(<1 nM)






(<1 nM)




(<1 nM)

(<1 nM)(<1 nM)

5


(<1 nM)(<1 nM)

(<1 nM)




(<1 nM)

10















(<1 nM)




HgC
(<1 nM)

15

115




(1.5 nM)




(~1 nM)


(<1 nM)




(~1 nM)




(<1 nM)




(<1 nM)




(<1 nM)




(<1 nM)




(<1 nM)





(<1 nM)







(<1 nM)







(<1 nM)




5



10





15





or pharmaceutically acceptable salts, solvates or esters thereof. The human IC_{50} values (in nM) have been provided for each compound (underneath the structure) above.

In another aspect of the invention, the compound according to Formula 1 is selected from the group consisting of compounds of the formulae:











5




or pharmaceutically acceptable salts, solvates or esters thereof.

In another embodiment, a compound is selected from the group consisting of the following formulae:



and






5

or pharmaceutically acceptable salts, solvates or esters thereof.


In another embodiment, the compound of Formula 1 is selected from the group consisting of

In another embodiment, the compound of Formula 1 is selected from the group consisting of Formula 7, Formula 8, Formula 9, Formula 10, Formula 11, Formula 12 and Formula 13 (all of compounds of Formula 7-13 have human IC₅₀ values of less than 1 nM):


10




15




Formula 10



Formula 11



Formula 12




Formula 13

and


or pharmaceutically acceptable salts, solvates or esters thereof.

In another embodiment, the compound of Formula 1 is selected from
 5 the group consisting of Formula 7, Formula 8, Formula 9, Formula 10,
 Formula 11, Formula 12, Formula 13, Formula 14, Formula 15, Formula 16, or
 Formula 17, or pharmaceutically acceptable salts, solvate or hydrates thereof,
 wherein Formulae 7-13 are as set forth above, and Formulae 13-17 are set
 forth below:




Formula 14


10



Formula 15



Formula 16



In yet another aspect, the compound according to Formula 1 is in purified form.

5 In another embodiment, this invention provides a pharmaceutical composition comprising at least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof in combination with at least one pharmaceutically acceptable carrier.

10 In still another embodiment, the invention provides a pharmaceutical composition of Formula 1, further comprising at least one additional agent, drug, medicament, antibody and/or inhibitor for treating a CXCR3 chemokine receptor mediated disease.

When administering a combination therapy to a patient in need of such administration, the therapeutic agents in the combination, or a pharmaceutical
15 composition or compositions comprising the therapeutic agents, may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like. The amounts of the various actives in such combination therapy may be different amounts (different dosage amounts) or same amounts (same dosage amounts). Thus, for non-limiting
20 illustration purposes, a compound of Formula III and an additional therapeutic agent may be present in fixed amounts (dosage amounts) in a single dosage unit (e.g., a capsule, a tablet and the like). A commercial example of such single dosage unit containing fixed amounts of two different active compounds is VYTORIN® (available from Merck Schering-Plough Pharmaceuticals,
25 Kenilworth, New Jersey).

In yet another embodiment, the present invention discloses methods for preparing pharmaceutical compositions comprising the inventive heterocyclic substituted piperazine compounds of Formula 1 as an active ingredient. In the pharmaceutical compositions and methods of the present
30 invention, the active ingredients will typically be administered in admixture with suitable carrier materials suitably selected with respect to the intended

form of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of
5 tablets or capsules, the active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like. Moreover, when desired or needed, suitable binders, lubricants, disintegrating agents
10 and coloring agents may also be incorporated in the mixture. Powders and tablets may be comprised of from about 5 to about 95 percent inventive composition. Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among the
15 lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include starch, methylcellulose, guar gum and the like. Sweetening and flavoring agents and preservatives may also be included where appropriate. Some of the terms noted above, namely disintegrants,
20 diluents, lubricants, binders and the like, are discussed in more detail below.

Additionally, the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e. anti-inflammatory activity and the like. Suitable
25 dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.

30 Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injections or addition of sweeteners and pacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.

For preparing suppositories, a low melting wax such as a mixture of
5 fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

Also included are solid form preparations which are intended to be
10 converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions may take the form of creams, lotions, aerosols
15 and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses
20 containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.

The quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 1.0 milligram to about 1,000 milligrams, preferably from about 1.0 to about 950 milligrams,
25 more preferably from about 1.0 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application. The actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art.

30 Generally, the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. The amount and frequency of the administration will be regulated according to the judgment of the attending clinician. A generally recommended daily dosage regimen for

oral administration may range from about 1.0 milligram to about 1,000 milligrams per day, in single or divided doses.

Some useful terms are described below:

Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients. Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.

Tablet- refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents. The tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.

Oral gels- refers to the active ingredients dispersed or solubilized in a hydrophilic semi-solid matrix.

Powders for constitution - refers to powder blends containing the active ingredients and suitable diluents which can be suspended in water or juices.

Diluent - refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose. The amount of diluent in the composition can range from about 10 to about 90% by weight of the total composition, preferably from about 25 to about 75%, more preferably from about 30 to about 60% by weight, even more preferably from about 12 to about 60%.

Disintegrants - refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments. Suitable disintegrants include starches; "cold water soluble" modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures. The amount of disintegrant in

the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to about 10% by weight.

Binders - refers to substances that bind or "glue" powders together and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose; starches derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate. The amount of binder in the composition can range from about 2 to about 20% by weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.

Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear. Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d,l-leucine. Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition can range from about 0.2 to about 5% by weight of the composition, preferably from about 0.5 to about 2%, more preferably from about 0.3 to about 1.5% by weight.

Glidents - materials that prevent caking and improve the flow characteristics of granulations, so that flow is smooth and uniform. Suitable glidents include silicon dioxide and talc. The amount of glident in the composition can range from about 0.1% to about 5% by weight of the total composition, preferably from about 0.5 to about 2% by weight.

Coloring agents - excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food

grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition, preferably from about 0.1 to about 1%.

Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.

Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures. Conventional methods for making other forms for administration such as, for example, capsules, suppositories and the like are also well known.

It will be apparent to those skilled in the art that many modifications, variations and alterations to the present disclosure, both to materials and methods, may be practiced. Such modifications, variations and alterations are intended to be within the spirit and scope of the present invention.

As stated earlier, the invention includes tautomers, enantiomers and other stereoisomers of the compounds also. Thus, as one skilled in the art knows, certain imidazole compounds may exist in tautomeric forms. Such variations are contemplated to be within the scope of the invention. Certain compounds of the present invention may exist in multiple crystalline forms or amorphous forms. All physical forms of the current invention are contemplated.

Compounds of this invention which contain unnatural proportions of atomic isotopes (i.e. "radiolabeled compounds") whether their use is therapeutic, diagnostic or as a research reagent are contemplated under this invention.

Another embodiment of the invention discloses the use of the pharmaceutical compositions disclosed above for treatment of diseases of a CXCR3 chemokine receptor mediated disease in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

In another embodiment, the method is directed to administering to the patient (a) an effective amount of at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one additional agent, drug, medicament, antibody and/or inhibitor for treating a CXCR3 chemokine receptor mediated disease, in combination with a pharmaceutically acceptable carrier.

In another embodiment, at least one compound of Formula 1 binds to a CXCR3 receptor.

The method can further comprise administering: (a) a therapeutically effective amount of at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one medicament selected from the group consisting of: disease modifying antirheumatic drugs; nonsteroidal anti-inflammatory drugs; COX-2 selective inhibitors; COX-1 inhibitors; immunosuppressives (such as cyclosporins and methotrexate); steroids (including corticosteroids such as glucocorticoids); PDE IV inhibitors, anti-TNF- α compounds, TNF- α -convertase (TACE) inhibitors, MMP inhibitors, cytokine inhibitors, glucocorticoids, other chemokine inhibitors such as CCR2 and CCR5, CB2-selective inhibitors, p38 inhibitors, biological response modifiers; anti-inflammatory agents and therapeutics. The disease can be an inflammatory disease (e.g., psoriasis, inflammatory bowel disease)

Another embodiment of this invention is directed to a method of inhibiting or blocking T-cell mediated chemotaxis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of at least one compound according to Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof.

Another embodiment of this invention is directed to a method of treating inflammatory bowel disease (such Crohn's disease, ulcerative colitis) in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

Another embodiment of this invention is directed to a method of treating inflammatory bowel disease in a patient in need of such treatment

comprising administering to the patient a therapeutically effective amount of:

(a) at least one compound of Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: sulfasalazine, 5-aminosalicylic acid, sulfapyridine, anti-TNF compounds, anti-IL-12 compounds, corticosteroids, glucocorticoids, T-cell receptor directed therapies (such as anti-CD3 antibodies), immunosuppressives, methotrexate, azathioprine, and 6-mercaptopurines.

Another embodiment of this invention is directed to a method of treating or preventing graft rejection in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

Another embodiment of this invention is directed to a method comprising administering to the patient a therapeutically effective amount of: (a) at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: cyclosporine A, FK-506, FTY720, beta-interferon, rapamycin, mycophenolate, prednisolone, azathioprine, cyclophosphamide and an antilymphocyte globulin.

Another embodiment of this invention is directed to a method of treating multiple sclerosis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: (a) at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: beta-interferon, glatiramer acetate, corticosteroids, glucocorticoids, methotrexate, azathioprine, mitoxantrone, VLA-4 inhibitors, FTY720, anti-IL-12 inhibitors, and CB2-selective inhibitors.

Another embodiment of this invention is directed to a method of treating multiple sclerosis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: a) at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at

least one compound selected from the group consisting of: methotrexate, cyclosporin, leflunomide, sulfasalazine, corticosteroids, β -methasone, β -interferon, glatiramer acetate, prednisone, etanercept, and infliximab.

Another embodiment of this invention is directed to a method of treating rheumatoid arthritis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: (a) at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: non-steroidal anti-inflammatory agents, COX-2 inhibitors, COX-1 inhibitors, immunosuppressives, cyclosporine, methotrexate, steroids, PDE IV inhibitors, anti-TNF- α compounds, MMP inhibitors, corticosteroids, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, caspase (ICE) inhibitors and other classes of compounds indicated for the treatment of rheumatoid arthritis.

Another embodiment of this invention is directed to a method of treating psoriasis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: a) at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: immunosuppressives, cyclosporins, methotrexate, steroids, corticosteroids, anti-TNF- α compounds, anti-IL compounds, anti-IL-23 compounds, vitamin A and D compounds and fumarates.

Another embodiment of this invention is directed to a method of treating ophthalmic inflammation (including, for e.g., uveitis, posterior segment intraocular inflammation, Sjogren's syndrome) or dry eye in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: a) at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: immunosuppressives, cyclosporins, methotrexate, FK506, steroids, corticosteroids, and anti-TNF- α compounds.

Another embodiment of this invention is directed to a method of treating a disease selected from the group consisting of: inflammatory

disease, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, graft rejection, psoriasis, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation (including e.g., uveitis, posterior segment intraocular inflammation, and Sjogren's syndrome),
5 tuberculoid leprosy and cancer in a patient in need of such treatment, such method comprising administering to the patient an effective amount of at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

Another embodiment of this invention is directed to a method of
10 treating a disease selected from the group consisting of inflammatory disease, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, graft rejection, psoriasis, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses and tuberculoid leprosy, ophthalmic inflammation, type I diabetes, viral meningitis and cancer in a patient in need of such
15 treatment, such method comprising administering to the patient an effective amount of (a) at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one medicament selected from the group consisting of: disease modifying antirheumatic drugs; nonsteroidal
20 antiinflammatory drugs; COX-2 selective inhibitors; COX-1 inhibitors; immunosuppressives; steroids; PDE IV inhibitors, anti-TNF- α compounds, MMP inhibitors, corticosteroids, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, biological response modifiers; anti-inflammatory agents and therapeutics.

25 Another embodiment of the invention discloses a method of making the inventive compounds disclosed above.

For the procedures described below, the following abbreviations are used:

Unless otherwise stated, the following abbreviations have the stated
30 meanings in the Examples below:

DBU= 1,8-diazabicyclo[5.4.0]undec-7-ene

DBN= 1,5-diazabicyclo[4.3.0]non-5-ene

DIPEA= N,N'-diisopropylethylamine

EDCI= 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide

HOBT= 1-hydroxybenzotriazole

DCC= dicyclohexylcarbodiimide

Dibal-H= diisobutylaluminum hydride

DMF = Dimethylformamide

5 LAH= lithium aluminum hydride

NaBH(OAc)₃= sodium triacetoxymborohydride

NaBH₄= sodium borohydride

NaBH₃CN= sodium cyanoborohydride

n-BOC= tert-butyloxycarbonyl

10 LDA= lithium diisopropylamide

p-TsOH= p-toluenesulfonic acid

m-CPBA= m-chloroperbenzoic acid

TMAD= N,N,N',N'-tetramethylazodicarboxamide

CSA= camphorsulfonic acid

15 NaHMDS= sodium hexamethyl disilylazide

HRMS= High Resolution Mass Spectrometry

HPLC= High Performance Liquid Chromatography

LRMS= Low Resolution Mass Spectrometry

nM= nanomolar

20 K_i= Dissociation Constant for substrate/receptor complex

pA₂= -logEC₅₀, as defined by J. Hey, *Eur. J. Pharmacol.*, (1995), Vol. 294, 329-335.

Ci/mmol= Curie/mmol (a measure of specific activity)

TLC= Thin layer chromatography

25 Tr= Triphenylmethyl

Tris= Tris (hydroxymethyl)aminomethane

General Preparative Schemes:


30 Compounds of the present invention can be prepared by a number of ways evident to one skilled in the art. Preferred methods include, but are not limited to, the general synthetic procedures described herein. One skilled in the art will recognize that one route will be optimal depending on the choice of appendage substituents. Additionally, one skilled in the art will recognize that in some cases the order of steps has to be controlled to avoid functional

group incompatibilities. One skilled in the art will recognize that a more convergent route (non-limiting example(s) include non-linear or preassembly of certain portions of the molecule) is a more efficient method of assembly of the target compounds. Two such methods for the preparation of compounds of general Formula 1 with variables R^1 , R^2 , R^3 , R^6 , R^7 , R^8 , R^{10} , R^{11} , R^{12} , R^{20} , ring D, X, Y, m, n, and p, are as defined above, and are shown in Scheme 1 and Scheme 2. **Pr¹**, **Pr²** and **Pr³** are protecting groups exemplified below.

The following schemes describe the methods of synthesis of compounds of Formula 1. In Scheme 1, the R^1R^2N group is introduced a late stage in the synthesis.

Scheme 1. Method A


Late Introduction of R^1R^2N -



Alternatively, the R^1R^2N group can be introduced earlier in the synthesis, as shown in Scheme 2.

Scheme 2. Method B.

Early Introduction of R^1R^2N -



The starting material and reagents used in preparing compounds described are either available from commercial suppliers such as Aldrich Chemical Co. (Wisconsin, USA) and Acros Organics Co. (New Jersey, USA) or were prepared by literature methods known to those skilled in the art.

The preparation of arylpiperazine compounds related to structure III has been reported in WO-03037862 (Nippon Shinyaku).

One skilled in the art will recognize that the synthesis of compounds of Formula 1 may require the need for the protection of certain functional groups (non-limiting example(s) include derivatization for the purpose of chemical compatibility with a particular reaction condition). Suitable protecting groups for a carboxylic acid (**Pr¹**, when **R⁷** and **R⁸** taken together is =O) is the methyl, ethyl, isopropyl, or benzyl ester and the like. A suitable protecting group for an amine (**Pr²** and **Pr³**) is methyl, benzyl, ethoxyethyl, t-butoxycarbonyl, phthaloyl and the like. All protecting groups can be appended to and removed by literature methods known to those skilled in the art.

One skilled in the art will recognize that the synthesis of compounds of Formula 1 may require the construction of an amide bond. Methods include but are not limited to the use of a reactive carboxy derivative (non-limiting example(s) include acid halide, or ester at elevated temperatures) or the use of an acid with a coupling reagent (non-limiting example(s) include EDCI, DCC) with an amine at 0°C to 100°C. Suitable solvents for the reaction are halogenated hydrocarbons, ethereal solvents, dimethylformamide and the like. The reaction may be conducted under pressure or in a sealed vessel.

One skilled in the art will recognize that the synthesis of compounds of Formula 1 may require the construction of an amine bond. One such method is but not limited to the reaction of a primary or secondary amine with a reactive carbonyl (non-limiting example(s) include aldehyde or ketone) under reductive amination conditions. Suitable reducing reagents of the intermediate imine are sodium borohydride, sodium triacetoxyborohydride and the like at 0°C to 100°C. Suitable solvents for the reaction are halogenated hydrocarbons, ethereal solvents, dimethylformamide and the like. Another such method is but not limited to the reaction of a primary or secondary amine with a reactive alkylating agent such as an alkyl halide, benzyl halide, mesylate, tosylate or the like. Suitable solvents for the reaction are halogenated hydrocarbons, ethereal solvents, dimethylformamide and the like. The reaction may be conducted under pressure or in a sealed vessel at 0°C to 100°C.

One skilled in the art will recognize that the synthesis of compounds of Formula 1 may require the reduction of a reducible functional group. Suitable reducing reagents include sodium borohydride, lithium aluminum hydride, diborane and the like at -20°C to 100°C. Suitable solvents for the reaction are halogenated hydrocarbons, ethereal solvents, dimethylformamide and the like.

One skilled in the art will recognize that the synthesis of compounds of Formula 1 may require the oxidation of a functional group. Suitable oxidizing reagents include oxygen, hydrogen peroxide, m-chloroperoxybenzoic acid and the like at -20°C to 100°C. Suitable solvents for the reaction are halogenated hydrocarbons, ethereal solvents, water and the like.

The starting materials and the intermediates of a reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like.

Such materials can be characterized using conventional means, including physical constants and spectral data.

General Description of Methods A & B

Step A. Amination of a Pyrazine

A suitably protected 2-halo pyrazine of structure **I** is reacted with a piperazine of structure **II** to form a compound of structure **III**. Preferably the reaction is carried out in a solvent such as dioxane in the presence of a base such as potassium carbonate or cesium carbonate. Alternatively, other leaving groups may replace the chlorine (O-mesyl, Br etc.) or a group capable of activation under the reaction conditions (H, OH, etc.) may be used.

Step A' (Method B)

A suitably protected 2-halo pyrazine of structure **I** is reacted with a piperazine of structure **XV** to form a compound of general structure **X**. Preferably the reaction is carried out in a solvent such as dioxane in the presence of a base such as potassium carbonate or cesium carbonate.

Step B.

A protected piperazine of structure **III** is deprotected to provide the secondary amine of structure **IV**. When **Pr²** is benzyl or substituted benzyl, deprotection can be effected by reaction under a pressure of hydrogen gas in

the presence of a catalyst such as palladium. When **Pr**² is ethoxyethyl, deprotection can be effected by reaction with trimethylsilyl iodide. When **Pr**² is t-butoxycarbonyl, deprotection can be effected with a strong acid such as trifluoroacetic acid.

5 Step C.

A piperazine of structure **IV** or **XII** is reacted with a ketone of structure **V** in the presence of a reducing agent to form a compound of structure **VI** or **XIII** where R¹² is hydrogen. General conditions for the reductive amination reaction are described above.

10 Step C'

A piperazine of structure **IV** or **XII** is reacted with a ketone of structure **V** in the presence of a reducing agent to form a compound of structure **VI** or **XIII** where R¹² is a cyanide residue. Typical conditions are the reaction of an equi-molar quantity of a piperazine of structure **IV** or **XII** and a ketone of structure in the presence of titanium isopropoxide in a halogenated solvent, such as methylene chloride for 1-48 hours. Subsequent addition of a cyanide source such as dimethylaluminum cyanide affords a compound of structure **VI** or **XIII** where R¹² is a cyanide residue.

Step C'' and Step D''

20 A piperazine of structure **IV** or **XII** is reacted with a ketone of structure **V** or **XVI** in the presence of a reducing agent to form a general compound of structure **VIII** or **X** respectively where R¹² is hydrogen. General conditions for the reductive amination reaction are described above.

Step D

25 Optionally, a compound of structure **XI**, when R³ is Cl or Br is reacted with an organometallic alkylating agent, such as alkyl boronic acid, or an alkyl halide in the presence of a metal to promote heterocoupling, or a nucleophile to yield a different structure of general structure **XII**, where the halogen at the R³ position has been replaced by the appropriate group described for R³.

30 Step D'

A protected piperidine of structure **VI** (Method A) or **XIII** (Method B) is deprotected to provide the secondary amine of structure **VII** (Method A) or **XIV** (Method B). When **Pr**² is benzyl or substituted benzyl, deprotection can be effected by reaction under a pressure of hydrogen gas in the presence of a

catalyst such as palladium. When **Pr**² is ethoxyethyl, deprotection can be effected by reaction with trimethylsilyl iodide. When **Pr**² is t-butoxycarbonyl, deprotection can be effected with a strong acid such as trifluoroacetic acid.

Step E

5 A secondary piperidine of structure **VII** or **XIV** is either alkylated or acylated to provide compounds of structure **VIII** or **X**. General methods for such alkylations and acylations are described above and are well known to those skilled in the art.

Step F

10 A suitable protected ester of structure **VIII** (Method A) or structure **III** (Method B) where **R**⁷ and **R**⁸ taken together is = O and **Pr**¹ is alkyl is reacted with a primary or secondary amine to provide compounds of structure **X** or **XI**.

 Optionally, functional group manipulation of a compound of structure **X** may be done to provide additional related compounds of structure **X**. Typical
15 conditions include the reaction of the ester and the amine in a polar solvent such as methanol in a sealed tube at 25°C to 100°C.

Step F'


 Optionally, functional group manipulation of a compound of structure **X** may be done to provide additional related compounds of structure **X**.

20 Compounds of Formula 1 can be prepared by the general methods outlined in Schemes 1 and 2. Synthesis of the specifically exemplified compounds, were prepared as described in detailed below. The following EXAMPLES are being provided to further illustrate the present invention. They are for illustrative purposes only; the scope of the invention is not to be
25 considered limited in any way thereby.

PREPARATIVE EXAMPLES


 The following examples are intended to illustrate, but not to limit, the scope of the invention.

Preparative Example 1.




A round bottomed flask was charged with methyl 6-amino 2,3-dichloro pyrazine 5-carboxylate (Aldrich, 25 g, 112.6 mmol), 2-S-Ethyl piperazine
5 (prepared as per Williams *et al. J. Med. Chem* 1996, 39, 1345, 83% active, 15.7 g, 112.7 mmol), cesium carbonate (100 g, 300 mmol) and 1,4 dioxane (400 ml). The flask was equipped with a reflux condenser and heated to 80°C. After 12 hours, the reaction was cooled, diluted with methylene chloride (~ 200 ml), and filtered through celite. The filtrate was washed once
10 with water and then concentrated to an oil. The crude product was purified by silica gel chromatography using a methanol/methylene chloride eluent (3% to 10% MeOH) to afford 30.8 g (91%) of the compound. MS, M+H = 300.

Preparative Example 2.




A round bottomed flask was charged with the product of Preparative Example 1 (0.9 g, 3 mmol), 2-amino ethanol (1.5 ml, 25 mmol) and 1,4 dioxane (20 ml). The reaction was heated at 80°C for 17 hours, and then
20 concentrated to an oil under vacuum. The title compound was isolated by preparative TLC (10/90 MeOH/MC), which provided 0.8 g (2.4 mmol, 81% yield). M+H = 330.

Preparative Example 3.




A round bottomed flask was charged with the product of Preparative Example 2 (0.79 g, 2.4 mmol), N-Boc piperidine-4-one (Lancaster, 1.4 g, 7.0 mmol), and methylene chloride (30 mL). NaB(OAc)₃H (1.5 g, 7.1 mmol) was added and the mixture stirred at room temperature for 12 hours. The reaction mixture was transferred to a separatory funnel and 1 N NaOH added. The crude product was extracted into methylene chloride (3 X), the organic extracts concentrated and further purified by TLC to afford 0.83 g of the title compound (68% yield). M+H = 513.

Preparative Example 4. Preparation of Table 1 Compound No. 334




A round bottomed flask was charged with the product of Preparative Example 2 (0.08 g, 0.24 mmol), N-(4-ketopiperidyl) 4-chlorobenzamide (0.170 g, 0.71 mmol), and methylene chloride (0.5 mL). NaB(OAc)₃H (.15 g, 0.71 mmol) was added and the mixture stirred at room temperature for 12 hours. The reaction mixture was transferred to a separatory funnel and 1 N NaOH added. The crude product was extracted into methylene chloride (3 X), the organic extracts concentrated and further purified by TLC to afford 0.06 g of the title compound (43% yield). .S M+H = 550

Preparative Example 5.




A round bottomed flask was charged with the product of Preparative Example 3 (6.67 g, 13 mmol), trifluoroacetic acid (60 ml, 778 mmol), methylene chloride (60 ml) and stirred at room temperature. After 4 hours, the reaction was concentrated *in vacuo*, and water (200 ml) and potassium carbonate (15 g, 108 mmol) were added to the residue. The product (4.85 g, 12 mmol, 91% yield) was isolated by extraction of the aqueous phase with methylene chloride (3 X) and used without further purification. M+H = 413.

Preparative Example 6. Preparation of Table 1, Compound No. 110

5 A round bottomed flask was charged with the product of Preparative Example 5 (0.05 g, 0.12 mmol), 4-chlorobenzaldehyde (0.05 g, 0.36 mmol), and methylene chloride (10 ml) and stirred at room temperature. After 2 hours $\text{NaB}(\text{OAc})_3\text{H}$ (75 mg, 0.35 mmol) was added and the reaction stirred an additional 15 hours. Additional methylene chloride (20 ml) was added, the
10 organic phase washed with 1N NaOH, dried over Na_2SO_4 and concentrated to an oil. The title compound was purified by TLC, which yielded 0.049g (76% yield). Compound No. 110: $\text{M}+\text{H} = 536$.

Reaction of the starting material of Preparative Example 6 with the appropriately substituted aldehyde afforded the following Compound


15 Numbers: 112, 113, 115, 117, 118, 120, 121, 123, 126, 133, 136, 140, 144, 154, 158, 161 and 162.

Preparative Example 7. Preparation of Table 1 Compound No. 185

20 A round bottomed flask was charged with the product of Preparative Example 5 (0.262 g, 0.635 mmol) and dimethylformamide (1.8 ml). 2-chloro-2-(3,4-difluorophenyl) acetic acid, methyl ester (0.14 g, 0.635 mmol) and triethylamine (0.27 ml, 1.9 mmol) were added and the reaction allowed to stir at room temperature. After 12 hours, ethyl acetate (10 ml) and water (10
25 ml) were added, the organic layer was separated and dried over MgSO_4 . The crude product was further purified by preparative TLC (10/90, MeOH/methylene chloride), which yielded isomer A (0.055 g, 15% yield) and isomer B (0.065 g 17% yield). Isomer A $\text{MS M}+\text{H} = 596$; Isomer B $\text{MS M}+\text{H} = 596$.


Reaction of the product of Preparative Example 7 with an appropriately substituted alpha-choro ester afforded the following Compound Numbers: 150, 175 192, 200, and 206.

Preparative Example 8. Preparation of Table 1 Compound No. 395




A round bottomed flask was charged with the product of Preparative Example 7 (Isomer A, 0.053 g, 0.089 mmol) and dry tetrahydrofuran (0.9 ml). Lithium borohydride (0.133 mL) of a 2 M solution in THF was added and the reaction was allowed to stir at room temperature. After 12 hours the reaction was diluted with methylene chloride (5 ml) and 1 N NaOH added (2 ml). The organic layer separated and dried over MgSO₄. The crude product was further purified by preparative TLC (10/90, MeOH/ methylene chloride) to afford the title compound, Isomer A (0.030 g, 60% yield). Isomer A MS M+H = 568.

Preparative Example 9. Preparation of Example No. 67



The product of Preparative Example 1 was reacted with N-4-chlorobenzyl piperidine-4-one under reductive amination conditions as in Preparative Example 4 to provide the title compound.


Preparative Example 10. Preparation of Example No. 301 – Lithium Salt



A round bottomed flask was charged with the product of Preparative Example 9 (0.85 g, 1.68 mmol), lithium hydroxide (2 ml of a 2 M LiOH in


The organic extract was dried over MgSO_4 and then concentrated in vacuo to an oil. Purification by Prep TLC using 94:6 Methylene chloride: MeOH eluent afforded the title compound (0.095 g, 47% yield). MS $\text{M}+\text{H} = 594.53$.

Preparative Example 13. Preparation of Table 1 Compound No. 107




The product of Preparative Example 12 (0.090 g, 0.15 mmol) and dry THF (5ml) were charged in a nitrogen flushed flask. Lithium Borohydride (0.25 ml of a 2 M THF solution) was added slowly at room temperature and allowed to stir overnight. After 16 hours, the reaction mixture was transferred to a separatory funnel and 1 N NaOH added. The crude product was extracted into methylene chloride (3 X), the organic extracts concentrated and further purified by prep TLC using 90:10 Methylene chloride: MeOH eluent to afford 0.081 g of the title compound (95% yield). MS $\text{M}+\text{H} = 566$.

Preparative Example 14




A round bottomed flask was charged with methyl 2-chloropyrazine-5-carboxylate (Lonza, 25.9 g, 145 mmol), 2-S-ethyl piperazine (prepared as per Williams et al J. Med. Chem **1996**, 39, 1345, 85% active, 28.0 g, 208 mmol), cesium carbonate (Aldrich, 110 g, 338 mmol) and 1,4 dioxane (400 ml). The resulting suspension was stirred at room temperature for 18 hours and then filtered. The solid was washed with ethyl acetate (3X400 ml). The combined organic solutions were concentrated on a rotary evaporator to remove the solvent. The residue was purified by flash chromatography on silica gel using 5% to 10% methanol in dichloromethane as an eluent to provide **A3** as a white solid (28.0 g, 77%).

Preparative Example 15.




The starting materials **A3** (28.0 g, 112 mmol), di-tert-butyl dicarbonate (24.5 g, 112 mmol), and dichloromethane (200 ml) were added to a 1000 ml flask. The resulting solution was stirred at room temperature for 20 hours, treated with 1.0 M aqueous NaOH solution (300 ml), and extracted with dichloromethane (3X200ml). The combined dichloromethane solutions were dried over sodium sulfate, concentrated on a rotary evaporator to remove the solvent. The residue was dried on house vacuum to afford **A4** as a gel (42 g) which was used for the next reaction without further purification.

Preparative Example 16.



The compound **A4** (crude, 42 g) and DMF (300 ml) were charged in a 1000 ml flask. To the stirring solution, NBS (32.0 g, 180 mmol) was added slowly at room temperature. The resulting solution was maintained at the same temperature with stirring for 17 hours, treated with saturated sodium sulfite (200 ml), diluted with ethyl acetate, and separated. The organic layer was washed with water (2X300ml), dried over sodium sulfate, and concentrated under reduced pressure. Purification of the residue by flash chromatography on silica gel using 3% methanol in dichloromethane afforded **A5** as an orange gel (47g, 98% for 2 steps).


Preparative Example 17.



A round bottomed flask was charged with **A5** (49.8 g, 116 mmol), trifluoroacetic acid (Acros, 100 ml), and dichloromethane (Aldrich, 100 ml). The resulting solution was stirred at room temperature for 4.5 hours and


concentrated to remove the acid. The residue was treated with solid potassium carbonate (35 g), water (100 ml) and 1.0 M NaOH solution at 0°C. The mixture was extracted with dichloromethane (4X300 ml) and the combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was dried on house vacuum to provide **A6** as a brown oil (36.20 g) which was used for the next reaction without purification.

Preparative Example 18.



A round-bottomed flask was charged with **A6** (36.0 g, 110 mmol), N-Boc piperidine-4-one (70.0 g, 351 mmol), and 1,2-dichloroethane (600 ml). The reducing reagent $\text{NaB}(\text{OAc})_3\text{H}$ (70.0 g, 330 mmol) was added slowly with stirring. The resulting suspension was stirred at room temperature for 3 days before it was treated with 1.0 M sodium hydroxide (800 ml) solution. The mixture was separated and the aqueous solution was extracted with dichloromethane (2x500 ml). The combined organic solutions were dried on sodium sulfate and concentrated on a rotary evaporator. The residue was purified by flash chromatography on silica gel using 20% ethyl acetate in hexanes and 2% methanol in dichloromethane as an eluent to provide **A7** as a red gel (38.0 g, 68%).

Preparative Example 19.




A round-bottomed flask was charged with **A7** (10.87 g, 21.21 mmol), methylboronic acid (Aldrich, 3.82 g, 63.82 mmol), potassium carbonate (Aldrich, 15.0 g, 109 mmol), and DMF (100 ml). The resulting suspension was degassed for 30 min via bubbling nitrogen prior to the addition of dichlorobis(triphenylphosphine)palladium (II) (Aldrich, 1.5 g, 2.1 mmol). The reaction mixture was maintained at 85°C for 20 hours with stirring, cooled to

room temperature, and filtered. The filtrate was diluted with ethyl acetate (800 ml), washed with water (4X300 ml), dried on sodium sulfate, and concentrated on rotary evaporator. The residue was purified by flash chromatography on silica gel using 2% methanol in dichloromethane as an eluent to afford **A8** as a red gel (5.95 g, 62%).


Preparative Example 20.

Step A



Benzaldehyde (19 mL, 19 g, 0.18 mol) was added to a solution of D-alanine methyl ester hydrochloride (25 g, 0.18 mol) in dry CH_2Cl_2 (300 mL). The solution was stirred at 22 °C for 19 h. The reaction mixture was cooled with an ice-water bath and solid sodium triacetoxyborohydride (46 g, 0.22 mol) was added in portions over ~15 min. The cooling bath was removed and the milky white solution was stirred at 22 °C for 7 h. The solvent was removed by rotary evaporation under reduced pressure and the resulting slush was partitioned between EtOAc (~100 mL) and 1 N HCl (~400 mL). The aqueous layer was extracted with EtOAc (~50 mL). The aqueous layer was adjusted to pH ~10 with 1 N NaOH (450 mL) and the milky aqueous layer was extracted immediately with EtOAc (3 x 250 mL). The combined organic layers were washed with brine (~250 mL), dried over anhydrous MgSO_4 , filtered and concentrated under reduced pressure to afford N-benzyl-D-alanine methyl ester (28 g, 80%) as a colorless semi-solid.


Step B.



To a solution of N-benzyl-D-alanine methyl ester (28 g, 0.15 mol) and EDCI·HCl (30.6 g, 0.160 mmol) in CH_2Cl_2 (250 mL) was added a solution of


The piperazine above (18.3 g, 84 mmol) was dissolved in CH₂Cl₂ (40 mL) and solid di-*t*-butyl dicarbonate (18.3 g, 84 mmol) was added. After stirring for 30 min at rt, the solvent was removed and the resulting yellow liquid was purified by flash column chromatography, eluting with 3:1 hexanes–Et₂O, to afford 1-Boc-2(*S*)-ethyl-4-benzyl-5(*R*)-methylpiperazine (**A36**) as a clear, colorless liquid (24.9 g, 93%).

Step D.



A mixture of 1-Boc-2(*S*)-ethyl-4-benzyl-5(*R*)-methylpiperazine (**A36**; 13.6 g, 43 mmol), glacial acetic acid (2.5 mL) and 10% Pd/C (4.5 g) in methanol (150 mL) was shaken under H₂ atmosphere (50 psi) for 24 h. The mixture was filtered through Celite[®] and the filter cake was washed copiously with EtOAc (~500 mL). The combined filtrates were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure to afford a clear colorless oil. Further co-evaporation with CH₂Cl₂ (200 mL) and Et₂O (2 x 200 mL) gave the desired 1-Boc-2(*S*)-ethyl-5(*R*)-methylpiperazine acetic acid salt (**A37**, 9.7 g) as a viscous oil.

Preparative Example 21.




1-Boc-2(*S*)-ethyl-5(*R*)-methylpiperazine acetic acid salt (10 g) was dissolved in dichloromethane (100 mL) and treated with triethylamine (4 mL, 3 g). Solvent was evaporated and the residue was passed through a silica gel column, eluting with 3% methanol (containing ammonia) in dichloromethane, to give 1-Boc-2(*S*)-ethyl-5(*R*)-methylpiperazine free base (7.2 g).

A round bottomed flask was charged with methyl 2-chloropyrazine-5-carboxylate (Lonza, 4.83 g, 28 mmol), 1-Boc-2(*S*)-ethyl-


5(R)-methylpiperazine free base (6.4 g, 28 mmol), cesium carbonate (Aldrich, 14 g, 42 mmol) and 1,4 dioxane (100 ml). The resulting suspension was stirred at 100 °C for 2 d and then filtered. The solid was washed with ethyl acetate (3X400 ml). The combined organic solutions were concentrated on a rotary evaporator to remove the solvent. The residue was purified by flash chromatography on silica gel using 1% methanol (containing 10% ammonium hydroxide) in dichloromethane as an eluent to provide **A38** (9.0 g, 90%), as a beige solid

Preparative Example 22.



The compound **A38** (9.0 g, 25 mmol) was dissolved in DMF (60 mL) and N-chlorosuccinimide (4.2 g, 32 mmol) was added. The reaction was stirred at rt for 18 h. The reaction mixture was diluted with ethyl acetate (500 mL) and washed sequentially with water (2 x 250 mL) and brine (250 mL). The organic phase was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to afford **A39** (7.95 g, 81%) as a pale yellow solid.

Preparative Example 23.



The compound **A39** (7.95 g, 20 mmol) was dissolved in methanol (15 mL) and was treated with HCl (25 mL, 4 M in dioxane, 100 mmol). After stirring for 3 h at rt, solvent was removed to afford a yellow crude product. The crude product was taken up in methanol (100 mL), treated with triethylamine (10 mL), the solution concentrated under reduced pressure, and the residue purified by flash column chromatography, eluting with 4.5% methanol (containing ammonia) in dichloromethane. The desired product **A40** (4.8 g, 81%).

Reaction of the Example No. 301-Lithium salt with an appropriately substituted amine as in example 11 above afforded the following Compound Numbers: 61, 65, 102, 105, 110, 209, 212, 213, 214, 215, 216, 217, 227, 229,
5 230, 233, 238, 245, 264, 273, 274, 277, 278, 279, 313, and 314.

Isolation of the compound at various stages of the reaction may be achieved by standard techniques such as, for example, filtration, evaporation of solvent and the like. Purification of the product, an intermediate and the like, may also be performed by standard techniques such as recrystallization,
10 distillation, sublimation, chromatography, conversion to a suitable derivative which may be recrystallized and converted back to the starting compound, and the like. Such techniques are well known to those skilled in the art.

The prepared compounds may be analyzed for their composition and purity as well as characterized by standard analytical techniques such as, for
15 example, elemental analysis, NMR, mass spectroscopy, and IR spectroscopy.

Biological Examples:

The inventive compounds can readily be evaluated to determine activity at the CXCR3 receptors by known methods, such as, for example,
20 development of a human CXCR3 (N-delta 4) Binding Assay.

Cloning and expression of human CXCR3 (N-delta 4):

The DNA encoding human CXCR3 was cloned by PCR using human genomic DNA (Promega, Madison, WI) as a template. The PCR primers were designed based on the published sequence of human orphan receptor GPR9
25 (1) with incorporated restriction sites, a Kozak consensus sequence, CD8 leader and Flag tag. The PCR product was subcloned into the mammalian expression vector pME18Sneo, a derivative of the SR-alpha expression vector (designated as pME18Sneo-hCXCR3 (N-delta 4).

IL-3-dependent mouse pro-B cells Ba/F3 were transfected by
30 electroporation in 0.4 ml Dulbecco's PBS containing 4×10^6 cells with 20 μ g of pME18Sneo-hCXCR3 (N-delta 4) plasmid DNA. Cells were pulsed at 400 Volts, 100 OHMs, 960 μ Fd. The transfected cells were under selection with 1 mg/ml G418 (Life Technologies, Gaithersburg, MD). G418-resistant Ba/F3

clones were screened for CXCR3 expression by specific binding of [¹²⁵I] IP-10 (NEN Life Science Products, Boston, MA).

Preparation of Ba/F3-hCXCR3 (N-delta 4) membranes :

Ba/F3 cells expressing human CXCR3 (N-delta 4) were pelleted and resuspended in the lysis buffer containing 10 mM HEPES , pH 7.5 and Complete[®] protease inhibitors (1 tablet per 100 ml) (Boehringer Mannheim, Indianapolis, IN) at a cell density of 20 x 10⁶ cells per ml. After 5 minute incubation on ice, cells were transferred to 4639 cell disruption bomb (Parr Instrument, Moline, IL) and applied with 1,500 psi of nitrogen for 30 minutes on ice. Large cellular debris was removed by centrifugation at 1,000 x g. Cell membrane in the supernatant was sedimented at 100,000 x g. The membrane was resuspended in the lysis buffer supplemented with 10% sucrose and stored at -80 °C. Total protein concentration of the membrane was determined by BCA method from Pierce (Rockford, IL).

Human CXCR3 (N-delta 4) scintillation proximity assay (SPA) :

For each assay point, 2 µg of membrane was preincubated for 1 hr with 300 µg wheat germ agglutinin (WGA) coated SPA beads (Amersham, Arlington Heights, IL) in the binding buffer (50 mM HEPES, 1 mM CaCl₂, 5 mM MgCl₂, 125 mM NaCl, 0.002% NaN₃, 1.0% BSA) at room temperature. The beads were spun down, washed once, resuspended in the binding buffer and transferred to a 96-well Isoplate (Wallac, Gaithersburg, MD). 25 pM of [¹²⁵I] IP-10 with tested compounds in a series of titration were added to start the reaction. After 3 hr reaction at room temperature, the amount of [¹²⁵I] IP-10 bound to the SPA beads was determined with a Wallac 1450 Microbeta counter.

The Ki ratings for the various compounds of the present invention are given in the afore-mentioned Table 1. From these ratings and value ranges, it would be apparent to the skilled artisan that the compounds of the invention have excellent utility as CXCR3 receptor antagonists.


While the present invention has been describe in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such

alternatives, medications and variations are intended to fall within the spirit and scope of the present invention.

CLAIMS

What is claimed is:

1. A compound having the general structure shown in Formula 1:



Formula 1

or pharmaceutically acceptable salts, solvates or esters thereof wherein:

X is N, O, alkyl, cycloalkyl, heteroaryl, heterocyclyl or heterocyclenyl;

ring D is a phenyl ring unsubstituted or optionally substituted with independently selected R^{20} moieties as stated below;

- R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkyl, alkoxy, alkenyl, carbonyl, cycloalkyl, alkyl-cycloalkyl-, cycloalkenyl, alkylaryl, arylalkyl, aryl, amino, alkylamino, amidinyl, carboxamido, cyano, hydroxyl, urea, $-N\equiv CH$, $=NCN$, $-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNHOSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-C(=S)N(H)alkyl$, $-N(H)-S(O)_2-alkyl$, $-N(H)C(=O)N(H)-alkyl$, $-S(O)_2alkyl$, $-S(O)_2N(H)alkyl$, $-S(O)_2N(alkyl)_2$, $-S(O)_2aryl$, $-C(=S)N(H)cycloalkyl$, $-C(=O)N(H)NH_2$, $-C(=O)alkyl$, -heteroaryl, heterocyclyl, and heterocyclenyl; or alternatively when X is N, the N taken together with the R^1 and R^2 forms a heterocycl, heteroaryl or $-N=C(NH_2)_2$;

- R^3 and R^6 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, aralkyl, $-CN$, CF_3 , haloalkyl, cycloalkyl, halogen, hydroxyalkyl, $-N=CH-(R^{31})$, $-C(=O)N(R^{30})_2$, $-N(R^{30})_2$, $-OR^{30}$, $-SO_2(R^{31})$, $-N(R^{30})C(=O)N(R^{30})_2$ and $-N(R^{30})C(=O)R^{31}$;

R^7 and R^8 are the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, heteroaryl, hydroxyl, $-CN$, alkoxy, alkylamino, $-N(H)S(O)_2alkyl$ and $-N(H)C(=O)N(H)alkyl$; or alternatively

R^7 and R^8 taken together is =O, =S, =NH, =N(alkyl), =N(Oalkyl), =N(OH) or cycloalkyl;

the R^{10} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclenyl, heterocyclyl, alkylaryl, arylalkyl, -CO₂H, hydroxyalkyl, -C(=O)N(R^{30})₂, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNHR³¹, -(CH₂)_qN(R^{31})₂, -OR³⁰, halogen, =O, and -C(=O)R³¹;

the R^{11} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclenyl, alkylaryl, arylalkyl, hydroxyalkyl, carboxamide, CO₂H, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNHR³¹, -(CH₂)_qN(R^{31})₂, -OR³⁰, halogen, =O, and -C(=O)R³¹;

R^{12} is selected from the group consisting of H, alkyl, -CN, -C(=O)N(R^{30})₂, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNHR³¹, -(CH₂)_qN(R^{31})₂, and -S(O₂)R³¹;

the R^{20} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkenyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylthiocarboxy, alkylheteroaryl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkenyl, aralkoxy, aralkoxycarbonyl, aralkylthio, aryl, aroyl, aryloxy, cyano, cycloalkyl, cycloalkenyl, formyl, guanidinyll, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, heterocyclenyl, hydroxyalkyl, haloalkoxy, hydroxamate, nitro, trifluoromethyl, trifluoromethoxy, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNH₂, -(CH₂)_qNHR³¹, -(CH₂)_qN(R^{31})₂, -(CH₂)_qC(=O)NHR³¹, -(CH₂)_qSO₂R³¹, -(CH₂)_qNHSO₂R³¹, -(CH₂)_qSO₂NHR³¹, -alkynylC(R^{31})₂OR³¹, -C(=O)R³⁰, -C(=O)N(R^{30})₂, -C(=NR³⁰)NHR³⁰, -C(=NOH)N(R^{30})₂, -C(=NOR³¹)N(R^{30})₂, -C(=O)OR³⁰, -N(R^{30})₂, -N(R^{30})C(=O)R³¹, -NHC(=O)N(R^{30})₂, -N(R^{30})C(=O)OR³¹, -N(R^{30})C(=NCN)N(R^{30})₂, -N(R^{30})C(=O)N(R^{30})SO₂(R^{31}), -N(R^{30})C(=O)N(R^{30})₂, -N(R^{30})SO₂(R^{31}), -N(R^{30})S(O)₂N(R^{30})₂, -OR³⁰, -OC(=O)N(R^{30})₂, -SR³⁰, -SO₂N(R^{30})₂, -SO₂(R^{31}), -OSO₂(R^{31}), -O(CH₂)_qSO₂R³¹, and -OSi(R^{30})₃; or alternatively two R^{20} moieties are linked together to form a five or six membered aryl, cycloalkyl, heterocyclyl, heterocyclenyl, or heteroaryl ring wherein said five or six membered aryl, cycloalkyl, heterocyclyl, heterocyclenyl, or heteroaryl ring is

fused to ring D and the fused ring is optionally substituted with 0-4 R^{21} moieties;

the R^{21} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkenyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylthiocarboxy, alkylheteroaryl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkenyl, aralkoxy, aralkoxycarbonyl, aralkylthio, aryl, aroyl, aryloxy, carboxamido, cyano, cycloalkyl, cycloalkenyl, formyl, guanidiny, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, heterocyclenyl, hydroxyalkyl, hydroxamate, nitro, trifluoromethoxy, $-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-alkynylC(R^{31})_2OR^{31}$, $-C(=O)R^{30}$, $-C(=O)N(R^{30})_2$, $-C(=NR^{30})NHR^{30}$, $-C(=NOH)N(R^{30})_2$, $-C(=NOR^{31})N(R^{30})_2$, $-C(=O)OR^{30}$, $-N(R^{30})_2$, $-N(R^{30})C(=O)R^{31}$, $-NHC(=O)N(R^{30})_2$, $-N(R^{30})C(=O)OR^{31}$, $-N(R^{30})C(=NCN)N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})SO_2(R^{31})$, $-N(R^{30})C(=O)N(R^{30})_2$, $-N(R^{30})SO_2(R^{31})$, $-N(R^{30})S(O)_2N(R^{30})_2$, $-OR^{30}$, $-OC(=O)N(R^{30})_2$, $-SR^{30}$, $-SO_2N(R^{30})_2$, $-SO_2(R^{31})$, $-OSO_2(R^{31})$, and $-OSi(R^{30})_3$;

Y is selected from the group consisting of $-(CR^{13}R^{13})_r$ -, $-CHR^{13}C(=O)-$, $-(CHR^{13})_rO-$, $-(CHR^{13})_rN(R^{30})-$, $-C(=O)-$, $-C(=NR^{30})-$, $-C(=N-OR^{30})-$, $-CH(C(=O)NHR^{30})-$, CH -heteroaryl-, $-C(R^{13}R^{13})_rC(R^{13})=C(R^{13})-$, $-(CHR^{13})_rC(=O)-$ and $-(CHR^{13})_rN(H)C(=O)-$; or alternatively Y is cycloalkyl, heterocyclenyl, or heterocyclyl wherein the cycloalkyl, heterocyclenyl, or heterocyclyl is fused with the phenyl ring marked D;

the R^{13} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, cycloalkyl, alkoxy, aryl, heteroaryl, heterocyclenyl, heterocyclyl, spiroalkyl, $-CN$, $-CO_2H$, $-C(=O)R^{30}$, $-C(=O)OR^{31}$, $-C(=O)N(R^{30})_2$, $-(CHR^{30})_qOH$, $-(CHR^{30})_qOR^{31}$, $-(CHR^{30})_qNH_2$, $-(CHR^{30})_qNHR^{31}$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-NH_2$, $-N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})_2$, $-N(R^{30})SO_2(R^{31})$, $-OH$, OR^{30} , $-SO_2N(R^{30})_2$, and $-SO_2(R^{31})$;

the R^{30} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, aryl, aralkyl, cycloalkyl, CN , $-(CH_2)_qOH$, $-(CH_2)_qOalkyl$, $-(CH_2)_qOalkylaryl$, $-(CH_2)_qOaryl$, $-(CH_2)_qOaralkyl$, $-(CH_2)_qOcycloalkyl$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHalkyl$,

$-(CH_2)_qN(alkyl)_2$, $-(CH_2)_qNHalkylaryl$, $-(CH_2)_qNHaryl$, $-(CH_2)_qNHaralkyl$, -
 $(CH_2)_qNHcycloalkyl$, $-(CH_2)_qC(=O)NHalkyl$, $-(CH_2)_qC(=O)N(alkyl)_2$, -
 $(CH_2)_qC(=O)NHalkylaryl$, $-(CH_2)_qC(=O)NHaryl$, $-(CH_2)_qC(=O)NHaralkyl$, -
 $(CH_2)_qC(=O)NHcycloalkyl$, $-(CH_2)_qSO_2alkyl$, $-(CH_2)_qSO_2alkylaryl$, -
5 $(CH_2)_qSO_2aryl$, $-(CH_2)_qSO_2aralkyl$, $-(CH_2)_qSO_2cycloalkyl$, $-(CH_2)_qNSO_2alkyl$, -
 $(CH_2)_qNSO_2alkylaryl$, $-(CH_2)_qNSO_2aryl$, $-(CH_2)_qNSO_2aralkyl$, -
 $(CH_2)_qNSO_2cycloalkyl$, $-(CH_2)_qSO_2NHalkyl$, $-(CH_2)_qSO_2NHalkylaryl$, -
 $(CH_2)_qSO_2NHaryl$, $-(CH_2)_qSO_2NHaralkyl$, $-(CH_2)_qSO_2NHcycloalkyl$,
heterocyclenyl, heterocyclyl, and heteroaryl;

10 the R^{31} moieties can be the same or different, each being
independently selected from the group consisting of alkyl, alkylaryl, aryl,
aralkyl, cycloalkyl, $-(CH_2)_qOH$, $-(CH_2)_qOalkyl$, $-(CH_2)_qOalkylaryl$, $-(CH_2)_qOaryl$,
 $-(CH_2)_qOaralkyl$, $-(CH_2)_qOcycloalkyl$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHalkyl$, -
 $(CH_2)_qN(alkyl)_2$, $-(CH_2)_qNHalkylaryl$, $-(CH_2)_qNHaryl$, $-(CH_2)_qNHaralkyl$, -
15 $(CH_2)_qNHcycloalkyl$, $-(CH_2)_qC(=O)NHalkyl$, $-(CH_2)_qC(=O)N(alkyl)_2$, -
 $(CH_2)_qC(=O)NHalkylaryl$, $-(CH_2)_qC(=O)NHaryl$, $-(CH_2)_qC(=O)NHaralkyl$, -
 $(CH_2)_qC(=O)NHcycloalkyl$, $-(CH_2)_qSO_2alkyl$, $-(CH_2)_qSO_2alkylaryl$, -
 $(CH_2)_qSO_2aryl$, $-(CH_2)_qSO_2aralkyl$, $-(CH_2)_qSO_2cycloalkyl$, $-(CH_2)_qNSO_2alkyl$, -
 $(CH_2)_qNSO_2alkylaryl$, $-(CH_2)_qNSO_2aryl$, $-(CH_2)_qNSO_2aralkyl$, -
20 $(CH_2)_qNSO_2cycloalkyl$, $-(CH_2)_qSO_2NHalkyl$, $-(CH_2)_qSO_2NHalkylaryl$, -
 $(CH_2)_qSO_2NHaryl$, $-(CH_2)_qSO_2NHaralkyl$, $-(CH_2)_qSO_2NHcycloalkyl$,
heterocyclenyl, heterocyclyl, and heteroaryl;

m is 0 to 4;

n is 0 to 4;

25 p is 0 to 5;

each q can be the same or different, each being independently
selected from 1 to 5; and

r is 1 to 4;

with the proviso that there are no two adjacent double bonds in any ring, and
30 that when a nitrogen is substituted by two alkyl groups, said two alkyl groups
may be optionally joined to each other to form a ring.

2. The compound according to Claim 1, wherein R^1 and R^2 are
independently absent or present, and if present each is independently
selected from the group consisting of H, alkyl, aryl, amino, alkoxy, halogen,

hydroxy, cycloalkyl, alkyl-cycloalkyl-, cycloalkenyl, arylalkyl, amidinyl, carboxamido, heteroaryl, heterocyclyl, heterocyclenyl, urea, $-S(O)_2$ alkyl, $-S(O)_2N(H)$ alkyl, $-S(O)_2N(alkyl)_2$, and $-C(=S)N(H)$ cycloalkyl.

3. The compound according to Claim 1, wherein R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkylaryl, alkyl-cycloalkyl-, aryl, heteroaryl, $-(CH_2)_qCF_3$,



$-(CH_2)_qOH$, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNH_2$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qN(R^{31})_2$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNHSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-(CH_2)_q$ -amidinyl, cyclopropyl, cyclopropylhydroxyl, cyclobutyl, cyclobutylhydroxy, cyclopentyl, and cyclopentylhydroxy; and

q is an integer from 1 to 5.


4. The compound according to Claim 1, wherein R^1 and R^2 are independently absent or present, and if present each is independently selected from the group consisting of H, $-CH_3$, fluorophenylmethylene, trifluoromethylphenylmethylene, indanyl, cyanophenylmethylene, difluorophenylmethylene, bromophenylmethylene, chlorophenylmethylene, $-CH_2CH_2O$ phenyl, cyclopentyl, bromochlorophenylmethylene, fluoro-chlorophenylmethylene, dichlorophenylmethylene, phenylmethylene,


$-(CH_2)_3$ phenyl, $-CH_2CF_3$, methoxyphenylmethylene, $-CH(CH_3)_2$, $-C_2H_5$, $-CH_2$ -cyclopropyl, $-(CH_2)_2CH_3$, cyclohexylmethylene, cyclohexyl, $-CH_2CH_2SO_2CH_3$, $-CH_2CH_2NH_2$, $-CH_2CH_2OCH_3$, cyclopropyl, CH_3 -cyclopropyl, isoxazolyl, $-CH_2CH_2OH$, $-CH_2CH_2O$ phenyl, $-CH_2CH_2CH_3$, $-NH_2$, $-(CH_2)_2NH_2$, pyrazolyl, 5-methyl-isoxazolyl, $-CH_2CH(OCH_2CH_3)_2$, $-OCH_3$, $-NHC(=O)NH_2$, chloropyridyl, pyridylmethylene, $-C(=O)NH$ cyclopropyl, $-C(=O)N(H)C_2H_5$, $-C(=O)N(H)CH_2CF_3$, $-C(=O)N(H)C(CH_3)_3$, $-C(=S)N(H)$ cyclopropyl, $-C(=O)NH_2$, $-C(=O)N(H)CH_3$, $-S(O)_2CH_3$, $-S(O)_2N(CH_3)_2$, $-S(O)_2CH_2CH_3$, $-C(=O)CH_3$, $-S(O)_2(CH_2)_2CH_3$, $-C(=O)N(H)$ cyclohexyl, $-C(=NH)NH_2$, $-C(=O)N(H)NH_2$, $-C(=O)N(H)CH(CH_3)_2$, thiazolyl, $-C(=O)N(CH_3)_2$, $-S(O)_2CH_2CF_3$, cyclopropyl, $-S(O)_2CF_3$, $-CH_2CH(OCH_2CH_3)_2$,

163




5








5

or when X is N, the N taken together with the R^1 and R^2 to which X is shown attached, forms a -N-cyclopropyl, -N-cyclobutyl, -N-cyclohexyl or




5. The compound according to Claim 1, wherein R^1 and R^2 are
- 10 independently absent or present, and if present each is independently selected from the group consisting of H, -CH₃, -C₂H₅, difluorophenylmethylene, cyclopropyl, CH₃-cyclopropyl-, dichlorophenylmethylene, -CH(CH₃)₂, cyclohexylmethylene, cyclohexyl, isoxazolyl, oxadiazolyl, aminooxadiazolyl, substituted isooxazolyl, substituted
- 15 oxadiazolyl, substituted aminooxadiazolyl, difluorophenyl, -CH₂CH₂OH, -CH₂CH₂N(CH₃)₂, -C(=O)N(H)cyclopropyl, -C(=O)N(H)C₂H₅, -C(=O)N(H)CH₂CF₃, -C(=O)N(H)CH(CH₃)₂, -C(=O)N(H)C(CH₃)₃, -C(=S)N(H)cyclopropyl, -C(=O)NH₂, -C(=O)N(H)CH₃, -S(O)₂CH₃, -S(O)₂N(CH₃)₂, -S(O)₂CH₂CH₃, -C(=O)CH₃, -S(O)₂(CH₂)₂CH₃,
- 20 -C(=O)N(H)cyclohexyl, -C(=NH)NH₂, -C(=O)N(H)NH₂, thiazolyl,



5

6. The compound according to Claim 1, wherein X is selected from the group consisting of N, O, -CH₃, -CH₂-, -CH-, -CH₂CH₃, -CH₂CN, -NH₂,



cyclopropyl,

and

10

7. The compound according to Claim 1, wherein R³ is selected from the group consisting of H, alkyl, haloalkyl, hydroxyalkyl, halogen, -N(R³⁰)₂, -OR³⁰ and -CF₃.

8. The compound according to Claim 7, wherein R³ is selected from the group consisting of H, -CH₃, -CH₂CH₃, cyclopropyl, -F, -Cl, OCH₃, OCF₃ and CF₃.

15


9. The compound according to claim 1, wherein R⁶ is selected from the group consisting of H, alkyl, halogen, hydroxyalkyl, -CN, -N(R³⁰)₂, -OR³⁰,

-N=CH-alkyl, and $\text{-NR}^{30}\text{C(=O)alkyl}$.


10. The compound according to Claim 9, wherein R^6 is selected from the group consisting of H, -NH_2 , -CH_3 , -CN and -F .

11. The compound according to Claim 1, wherein R^7 and R^8 are the same
 5 or different, each being independently selected from the group consisting of H, $\text{-(CH}_2)_q\text{OH}$, $\text{-(CH}_2)_q\text{Oalkyl}$, $\text{-(CH}_2)_q\text{N(H)-alkyl}$, $\text{-(CH}_2)_q\text{N(H)-S(O)}_2\text{alkyl}$, and $\text{-(CH}_2)_q\text{N(H)-CO-N(H)alkyl}$; or alternatively R^7 and R^8 taken together is =O, =N(Oalkyl), or =S.

12. The compound according to Claim 1, wherein R^7 and R^8 are the same
 10 or different, each being independently selected from the group consisting of H, -CH_3 , and -OH ; or alternatively R^7 and R^8 taken together with the carbon atom to which R^7 and R^8 are shown attached, is



13. The compound according to Claim 1, wherein R^7 and R^8 are each H; or
 15 alternatively R^7 and R^8 taken together together with the carbon atom to which R^7 and R^8 are shown attached, is




14. The compound according to Claim 1, wherein R^{10} is selected from the
 20 group consisting of H, alkyl, aralkyl, hydroxyalkyl, and carbonyl.

15. The compound according to Claim 14, wherein R^{10} is selected from the group consisting of -CH_3 , $\text{-CH}_2\text{CH}_3$ and $\text{-CH}_2\text{CH}_2\text{CH}_3$, and m is 0 - 2.

16. The compound according to Claim 1, wherein R^{11} is selected from the group consisting of H, alkyl, hydroxyalkyl and carbonyl.

17. The compound according to Claim 16, wherein R^{11} is H or $-CH_3$.
18. The compound according to Claim 1, wherein R^{12} is selected from the group consisting of H, CN, $-C(=O)N(R^{30})_2$ and alkyl.
19. The compound according to Claim 18, wherein R^{12} is selected from the group consisting of H, $-CH_3$, CN and $-CH_2CH_3$.
20. The compound according to Claim 1, wherein the phenyl ring D is substituted by independently selected 1-4 R^{20} moieties.
21. The compound according to Claim 1, wherein the R^{20} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylheteroaryl, alkylsulfinyl, alkoxy carbonyl, aminoalkyl, amidinyl, aralkyl, aralkoxy, aryl, aryloxy, cyano, cycloalkyl, cycloalkenyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxyalkyl, trifluoromethyl, trifluoromethoxy, $-(CH_2)_qOR^{31}$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-alkynylC(R^{31})_2OR^{31}$, $-C(=O)R^{30}$, $-C(=O)N(R^{30})_2$, $-C(=O)OR^{30}$, $-N(R^{30})_2$, $-N(R^{30})C(=O)R^{31}$, $-NHC(=O)N(R^{30})_2$, $-N(R^{30})C(=O)OR^{31}$, $-N(R^{30})C(=NCN)N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})_2$, $-N(R^{30})SO_2(R^{31})$, $-N(R^{30})SO_2N(R^{30})_2$, $-OR^{30}$, $-OC(=O)N(R^{30})_2$, $-SR^{30}$, $-SO_2N(R^{30})_2$, $-SO_2(R^{31})$, $-OSO_2(R^{31})$, $-O(CH_2)_qSO_2R^{31}$, and $-OSi(R^{30})_3$.
22. The compound according to Claim 1, wherein the R^{20} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkoxy, amino, halogen, CN, CH_3 , CF_3 , OCH_3 , OCF_3 , $-(CH_2)_qOR^{31}$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, $-alkynylC(R^{31})_2OR^{31}$, $-C(=O)R^{30}$, $-C(=O)OR^{30}$, $-N(R^{30})_2$, $-N(R^{30})C(=O)R^{31}$, $-NHC(=O)N(R^{30})_2$, $-N(R^{30})C(=O)OR^{31}$, $-N(R^{30})C(=NCN)N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})_2$, $-OR^{30}$, $-OC(=O)N(R^{30})_2$, $-O(CH_2)_qSO_2R^{31}$ and $-OSO_2(R^{31})$.
23. The compound according to Claim 1, wherein two R^{20} moieties are linked together to form a five or six membered aryl, cycloalkyl, heterocyclenyl, heterocyclyl or heteroaryl ring wherein said five or six membered aryl, cycloalkyl, heterocyclenyl, heterocyclyl, and heteroaryl ring is fused to ring D and the fused ring is optionally substituted with 0 to 4 R^{21} moieties.
24. The compound according to Claim 1, wherein the R^{20} moieties can be the same or different, each being independently selected from the group

consisting of H, -CN, -CH₃, -CF₃, -CH₂OH, -CO₂H, -CO₂CH₃, -NH₂, -NHCH₃, -OCF₃, -OH, F, Cl, Br, -C(=NOH)NH₂, -OCH₂CH₂S(O₂)CH₃, -C(=O)NH₂,



25. The compound according to Claim 1, wherein Y is selected from the group consisting of: -(CHR¹³)_r-, -(CR¹³R¹³)_r-, -C(=O)- and -CHR¹³C(=O)-.

26. The compound according to Claim 1, wherein Y is selected from the group consisting of: -CH₂-, -CH(CH₃)-, -CH(CH₂OH)-, -C(=O)- and -CH(CO₂alkyl)-.

27. The compound according to Claim 1, wherein m is 0-3.

28. The compound according to Claim 1, wherein n is 0-2.

29. The compound according to Claim 1, wherein q is 1, 2 or 3.

30. The compound according to Claim 1, wherein r is 1 or 2.

31. The compound according to Claim 1, wherein X is N;

R¹ and R² are independently absent or present, and if present each is independently selected from the group consisting of H, alkylaryl, aryl, heteroaryl, -(CH₂)_qCF₃, -(CH₂)_qOH, -(CH₂)_qOR³¹, -(CH₂)_qNH₂, -(CH₂)_qNHR³¹, -(CH₂)_q-N(R³¹)₂, -(CH₂)_qC(=O)NHR³¹, -(CH₂)_qSO₂R³¹, -(CH₂)_qNHSO₂R³¹, -(CH₂)_qSO₂NHR³¹, -(CH₂)_q-amidinyl, cyclopropyl, alkyl-cyclopropyl-, cyclopropylhydroxyl, cyclobutyl, cyclobutylhydroxy, cyclopentyl, and cyclopentylhydroxy;

R³ is selected from the group consisting of H, alkyl, haloalkyl, hydroxyalkyl, halogen, -N(R³⁰)₂, -OR³⁰ and -CF₃;

R⁶ is selected from the group consisting of H, alkyl, halogen, hydroxyalkyl, -CN, -N(R³⁰)₂, -OR³⁰, -N=CH-alkyl, and -NR³⁰C(=O)alkyl;


R⁷ and R⁸ are independently selected from the group consisting of =O, =S, =NH, =NOH, and =N(Oalkyl);

R¹⁰ is selected from the group consisting of H, alkyl, aralkyl, hydroxyalkyl, and carbonyl;

R¹¹ is selected from the group consisting of H, alkyl, hydroxyalkyl, and carbonyl;

R^{12} is selected from the group consisting of H, CN, $-C(=O)N(R^{30})_2$ and alkyl;

the R^{20} moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkoxy, amino, halogen, CN, CH_3 , CF_3 , OCH_3 , OCF_3 , $-(CH_2)_qOR^{31}$, $-(CH_2)_qNHR^{31}$, $-(CH_2)_qC(=O)NHR^{31}$, $-(CH_2)_qSO_2R^{31}$, $-(CH_2)_qNSO_2R^{31}$, $-(CH_2)_qSO_2NHR^{31}$, alkynyl $C(R^{31})_2OR^{31}$, $-C(=O)R^{30}$, $-C(=O)OR^{30}$, $-N(R^{30})_2$, $-N(R^{30})C(=O)R^{31}$, $-NHC(=O)N(R^{30})_2$, $-N(R^{30})C(=O)OR^{31}$, $-N(R^{30})C(=NCN)N(R^{30})_2$, $-N(R^{30})C(=O)N(R^{30})_2$, $-OR^{30}$, $-OC(=O)N(R^{30})_2$,



Y is selected from the group consisting of: $-CH_2-$, $-CH(CH_3)-$, $-CH(CH_2OH)-$, $-C(=O)-$ and $-CH(CO_2alkyl)-$;


m is 0-2;

15 n is 0-2;

q is 1 or 2; and







r is 1 or 2.









32. The compound according to Claim 1, represented by the following structural Formula:

















wherein the various terms are as defined in Claim 1.









33. The compound according to Claim 1, selected from the group consisting of:








Compound No.	Compound Structure
1	
2	
3	
4	
5	
6	









7	
8	
9	
10	
11	
12	
13	
14	









15	
16	
17	
18	
19	
20	
21	









22	
23	
24	
25	
26	
27	
28	









29	
30	
31	
32	
33	
34	
35	
36	









37	
38	
39	
40	
41	
42	
43	









44	
45	
46	
47	
48	
49	
50	
51	

52	
53	
54	
55	
56	
57	
58	
59	









60	
61	
62	
63	
64	
65	
66	
67	









68	
69	
70	
71	
72	
73	
74	
75	









76	
77	
78	
79	
80	
81	
82	
83	








84	
85	
86	
87	
88	
89	
90	
91	








92	
93	
94	
95	
96	
97	
98	
99	









100	
101	
102	
103	
104	
105	
106	
107	








108	
109	
110	
111	
112	
113	
114	
115	









116	
117	
118	
119	
120	
121	
122	
123	









124	
125	
126	
127	
128	
129	
130	









131	
132	
133	
134	
135	
136	
137	

138	
139	
140	
141	
142	
143	
144	
145	









154	
155	
156	
157	
158	
159	
160	








161	
162	
163	
164	
165	
166	
167	
168	









169	
170	
171	
172	
173	
174	
175	
176	









177	
178	
179	
180	
181	
182	
183	
184	










185	
186	
187	
188	
189	
190	
191	
192	









193	
194	
195	
196	
197	
198	
199	
200	

201	
202	
203	
204	
205	
206	
207	









208	
209	
210	
211	
212	
213	
214	
215	









216	
217	
218	
219	
220	
221	
222	
223	









224	
225	
226	
227	
228	
229	
230	
231	
232	









233	
234	
235	
236	
237	
238	
239	
240	









241	
242	
243	
244	
245	
246	
247	
248	









249	
250	
251	
252	
253	
254	
255	
256	









257	
258	
259	
260	
261	
262	
263	
264	










265	
266	
267	
268	
269	
270	
271	
272	








273	
274	
275	
276	
277	
278	
279	
280	









281	
282	
283	
284	
285	
286	
287	
288	









289	
290	
291	
292	
293	
294	
295	
296	









297	
298	
299	
300	
301	
302	
303	
304	









305	
306	
307	
308	
309	
310	
311	
312	
313	









314	
315	
316	
317	
318	
319	
320	









321	
322	
323	
324	
325	
326	
327	
328	

329	
330	
331	
332	
333	
334	
335	
336	







337	
338	
339	
340	
341	
342	
343	
344	








345	
346	
347	
348	
349	
350	
351	
352	








353	
354	
355	
356	
357	
358	
359	
360	









361	
362	
363	
364	
365	
366	
367	
368	






369	
370	
371	
372	
373	
374	
375	
376	






377	
378	
379	
380	
381	
382	






383	
384	
385	
386	
387	
388	
389	






390	
391	
392	
393	
394	
395	
396	






397	
398	
399	
400	
401	
402	
403	
404	










405	
406	
407	
408	
409	
410	











	 <chem>CCN1CCN(C1CN2C=NC(=C(N2)C(=O)NCO)N)C3CCN(C3)Cc4ccc(Cl)c(OC(=O)S)cc4</chem>
411	 <chem>CCN1CCN(C1CN2C=NC(=C(N2)N)N)C3CCN(C3)Cc4ccc(Cl)c(OC(=O)S)cc4</chem>
412	 <chem>CCN1CCN(C1CN2C=NC(=C(N2)C)C(=O)N)C3CCN(C3)Cc4ccc(Cl)cc4</chem>
413	 <chem>CCN1CCN(C1CN2C=NC(=C(N2)C(=O)NCO)N)C3CCN(C3)Cc4ccc(F)c(OC(=O)S)cc4</chem>
414	 <chem>CCN1CCN(C1CN2C=NC(=C(N2)C(=O)N)Br)C3CCN(C3)Cc4ccc(Cl)cc4C(=O)N</chem>
415	











	
416	
417	
418	
419	
420	

	
421	
422	
423	
424	











425	
426	
427	
428	
429	

430	
431	
432	
433	
434	
435	
436	
437	
438	

439	
440	
441	
442	
443	
444	
445	
446	
447	
448	

449	
450	
451	
452	
453	
454	
455	
456	
457	
458	


459	
460	
461	
462	
463	
464	
465	
466	
467	
468	


469	
470	
471	
472	
473	
474	
475	
476	
477	
478	


479	
480	
481	
482	
483	
484	
485	
486	
487	
488	













489	
490	
491	
492	


34. The compound according to Claim 33, selected from the group consisting of:













or pharmaceutically acceptable salts, solvates or esters thereof.


35. A compound of Formula 7, Formula 8, Formula 9, Formula 10, Formula 11, Formula 12, Formula 13, Formula 14, Formula 15, Formula 16, or Formula 17:




Formula 7




Formula 8




Formula 9




Formula 10




Formula 11




Formula 12




Formula 13




Formula 14



Formula 15



Formula 16



Formula 17

or pharmaceutically acceptable salts, solvates or esters thereof.

36. A compound according to Claim 1 in purified form.

37. A pharmaceutical composition comprising at least one compound of Claim 1 or 33, or a pharmaceutically acceptable salt, solvate or ester thereof, in combination with at least one pharmaceutically acceptable carrier.

5 38. The pharmaceutical composition of claim 37, further comprising at least one additional agent, drug, medicament, antibody and/or inhibitor for treating a CXCR3 chemokine receptor mediated disease.

39. A method of treating a CXCR3 chemokine receptor mediated disease in a patient in need of such treatment comprising administering to the patient
10 a therapeutically effective amount of at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

40. The method according to Claim 39 comprising administering to the patient (a) an effective amount of at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently
15 or sequentially with (b) at least one additional agent, drug, medicament, antibody and/or inhibitor for treating a CXCR3 chemokine receptor mediated disease, in combination with a pharmaceutically acceptable carrier.

41. The method according to Claim 39 wherein the compound binds to a CXCR3 receptor.

20 42. The method according to Claim 39 comprising administering: (a) a therapeutically effective amount of at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one medicament selected from the group consisting of: disease modifying antirheumatic drugs; nonsteroidal anti-
25 inflammatory drugs; COX-2 selective inhibitors; COX-1 inhibitors; immunosuppressives; steroids; PDE IV inhibitors, anti-TNF- α compounds, TNF-alpha-convertase inhibitors, cytokine inhibitors, MMP inhibitors, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, p38 inhibitors, biological response modifiers; anti-inflammatory agents and therapeutics.

30 43. The method according to Claim 39 wherein the disease is an inflammatory disease.

44. A method of inhibiting or blocking T-cell mediated chemotaxis in a patient in need of such treatment the method comprising administering to the

patient a therapeutically effective amount of at least one compound according to Claim 1 or a pharmaceutically acceptable salt, solvate or ester thereof.

45. A method of treating inflammatory bowel disease in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

46. The method according to Claim 45, the method comprising administering to the patient a therapeutically effective amount of: (a) at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: sulfasalazine, 5-aminosalicylic acid, sulfapyridine, anti-TNF compounds, anti-IL-12 compounds, corticosteroids, glucocorticoids, T-cell receptor directed therapies, immunosuppressives, methotrexate, azathioprine, and 6-mercaptopurines.

47. A method of treating or preventing graft rejection in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

48. The method according to Claim 47, the method comprising administering to the patient a therapeutically effective amount of: (a) at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: cyclosporine A, FK-506, FTY720, beta-interferon, rapamycin, mycophenolate, prednisolone, azathioprine, cyclophosphamide and an antilymphocyte globulin.

49. A method of treating multiple sclerosis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: (a) at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: beta-interferon, glatiramer acetate, corticosteroids, glucocorticoids, methotrexate, azathioprine, mitoxantrone, VLA-4 inhibitors, FTY720, anti-IL-12 compounds, and CB2-selective inhibitors.

50. A method of treating multiple sclerosis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: a) at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or
5 sequentially with (b) at least one compound selected from the group consisting of: methotrexate, cyclosporin, leflunomide, sulfasalazine, corticosteroids, β -methasone, β -interferon, glatiramer acetate, prednisone, etonercept, and infliximab.

51. A method of treating rheumatoid arthritis in a patient in need of such
10 treatment the method comprising administering to the patient a therapeutically effective amount of: (a) at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: non-steroidal anti-inflammatory agents, COX-2 inhibitors,
15 COX-1 inhibitors, immunosuppressives, cyclosporine, methotrexate, steroids, PDE IV inhibitors, anti-TNF- α compounds, MMP inhibitors, corticosteroids, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, caspase (ICE) inhibitors and other classes of compounds indicated for the treatment of rheumatoid arthritis.

20 52. A method of treating psoriasis in a patient in need of such treatment the method comprising administering to the patient a therapeutically effective amount of: a) at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group
25 consisting of: immunosuppressives, cyclosporine, methotrexate, steroids, corticosteroids, anti-TNF- α compounds, anti-IL compounds, anti-IL-23 compounds, vitamin A and D compounds and fumarates.

53. A method of treating ophthalmic inflammation or dry eye in a patient in need of such treatment the method comprising administering to the patient a
30 therapeutically effective amount of: a) at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one compound selected from the group consisting of: immunosuppressives, cyclosporine, methotrexate, FK506, steroids, corticosteroids, and anti-TNF- α compounds.

54. A method of treating a disease selected from the group consisting of: inflammatory disease, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, graft rejection, psoriasis, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, tuberculoid leprosy and cancer in a patient in need of such treatment, such method comprising administering to the patient an effective amount of at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof.

55. A method of treating a disease selected from the group consisting of: inflammatory disease, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, graft rejection, psoriasis, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses and tuberculoid leprosy, ophthalmic inflammation, type I diabetes, viral meningitis and cancer in a patient in need of such treatment, such method comprising administering to the patient an effective amount of (a) at least one compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or ester thereof concurrently or sequentially with (b) at least one medicament selected from the group consisting of: disease modifying antirheumatic drugs; nonsteroidal antiinflammatory drugs; COX-2 selective inhibitors; COX-1 inhibitors; immunosuppressives; steroids; PDE IV inhibitors, anti-TNF- α compounds, MMP inhibitors, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, biological response modifiers; anti-inflammatory agents and therapeutics.